<SEC-DOCUMENT>0001193125-25-286466.txt : 20251118
<SEC-HEADER>0001193125-25-286466.hdr.sgml : 20251118
<ACCEPTANCE-DATETIME>20251118172737
ACCESSION NUMBER:		0001193125-25-286466
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20251118
DATE AS OF CHANGE:		20251118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Olema Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001750284
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				300409740
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-284146
		FILM NUMBER:		251496020

	BUSINESS ADDRESS:	
		STREET 1:		780 BRANNAN STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94103
		BUSINESS PHONE:		(415) 651-3316

	MAIL ADDRESS:	
		STREET 1:		780 BRANNAN STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94103
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d846460d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV STYLE="position:relative; overflow:visible; width:686pt; height:30pt; transform-origin:bottom left; transform: rotate(-90deg) translate(-100%, 100%) translateX(30pt);">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#ff4338"><B>The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these
securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and they are not soliciting an offer to buy
these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P></DIV><DIV STYLE="position:relative; overflow:visible; margin-left:48pt; margin-right:48pt; transform: translateY(-30pt);">
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR> Registration No. 333-284146
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>Subject to completion, dated November&nbsp;18, 2025 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus dated
January&nbsp;15, 2025) </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g846460g81e43.jpg" ALT="LOGO" STYLE="width:2.32027in;height:0.664825in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to Purchase Shares of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering &#8195;&#8195;&#8195;&#8195; shares of our common stock, or for certain investors that so choose, in lieu of shares of common stock, <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase &#8195;&#8195;&#8195;&#8195; shares of our common stock (the <FONT STYLE="white-space:nowrap">&#8220;pre-funded</FONT> warrants&#8221;) pursuant to this prospectus supplement and the
accompanying prospectus. The purchase price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will equal the price per share that our shares of common stock are being sold to the public in this offering, minus $0.0001, and the
exercise price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will equal $0.0001 per share. The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be exercisable immediately and each
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant is exercisable for one share of our common stock. This preliminary prospectus supplement also relates to the offering of the shares of common stock issuable upon exercise of such <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the Nasdaq Global Select Market under the symbol &#8220;OLMA.&#8221;
On November&nbsp;17, 2025, the last reported sale price of our common stock on the Nasdaq Global Select Market was $8.52 per share. There is no established public trading market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants,
and we do not expect a market to develop. We do not intend to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on the Nasdaq Global Select Market or on any other national securities exchange or nationally recognized trading
system. Without an active trading market, the liquidity of the warrants will be limited </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See &#8220;<A HREF="#supptoc846460_3">Risk Factors</A>&#8221; beginning on page <FONT
STYLE="white-space:nowrap">S-6</FONT> of this prospectus supplement. You should read the entire prospectus supplement and the accompanying prospectus, including any information incorporated by reference herein or therein, carefully before you make
your investment decision. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a &#8220;smaller reporting company&#8221; as defined under federal securities laws and, as such, have elected to
comply with certain reduced public company reporting requirements. See &#8220;Prospectus Supplement Summary&#8212;Implications of Being a Smaller Reporting Company.&#8221; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR><FONT STYLE="white-space:nowrap">Pre-Funded</FONT><BR>Warrant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to Olema Pharmaceuticals, Inc., before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See &#8220;Underwriting&#8221; for a description of the compensation payable to the underwriters.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option to purchase up to &#8195;&#8195;&#8195;&#8195; additional shares of common stock from us at
the public offering price, less underwriting discounts and commissions, within 30 days from the date of this prospectus supplement. See &#8220;Underwriting&#8221; for more information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the securities to purchasers on or about&#8195;&#8195;&#8195;&#8195;, 2025. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>TD Cowen </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;&#8195;, 2025 </B></P></DIV> <p STYLE="clear:both; font-size:1pt; height:0">&nbsp;</p>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc846460_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-ii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc846460_2">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc846460_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc846460_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc846460_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc846460_6">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc846460_7">DESCRIPTION OF THE SECURITIES WE ARE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc846460_8">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-15</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc846460_9">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-22</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc846460_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-30</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc846460_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-30</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc846460_12">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-30</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc846460_13">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-30</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_9">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_10a">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_12">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_13">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc846460_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is part of the registration statement that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) using a
&#8220;shelf&#8221; registration process and consists of two parts. The first part is this prospectus supplement, which describes the terms of this offering of our securities and also adds to and updates information contained in the accompanying
prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus that we initially filed with the SEC on January&nbsp;6, 2025 and that was declared
effective by the SEC on January&nbsp;15, 2025, included in our registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-284146)</FONT> including the documents incorporated by
reference therein, provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus
supplement, on the one hand, and the information contained in the accompanying prospectus or in any document incorporated by reference that was filed with the SEC, before the date of this prospectus supplement, on the other hand, you should rely on
the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example, a document incorporated by reference in the accompanying
prospectus&#8212;the statement in the document having the later date modifies or supersedes the earlier statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not, and the underwriters have
not, authorized anyone to provide any information other than that contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or in any free writing prospectus that we have authorized for use in connection with
this offering. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The information contained in this prospectus supplement, the accompanying
prospectus, any free writing prospectus that we have authorized for use in connection with this offering, including the documents incorporated by reference herein or therein, is accurate only as of the respective dates thereof, regardless of the
time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of our securities. It is important for you to read and consider all information contained in this prospectus supplement, the accompanying prospectus and
any free writing prospectus that we have authorized for use in connection with this offering, including the documents incorporated by reference herein and therein, in making your investment decision. You should also read and consider the information
in the documents to which we have referred you in the sections titled &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; in this prospectus supplement and in the accompanying
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and the underwriters are offering to sell, and seeking offers to buy, our securities only in jurisdictions in which offers and sales are
permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of our securities in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this
prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of our securities and the distribution of this prospectus supplement and the accompanying prospectus outside
the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and
the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as
otherwise indicated herein or as the context otherwise requires, references in this prospectus supplement, the accompanying prospectus and the information incorporated by referenced herein or therein to &#8220;Olema,&#8221; &#8220;Olema
Oncology,&#8221; &#8220;the company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms refer to Olema Pharmaceuticals, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc846460_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere or incorporated by reference in this prospectus supplement and the accompanying prospectus. This
summary does not contain all of the information you should consider before investing in our securities. Before you decide to invest in our securities, you should carefully read the prospectus supplement and the accompanying prospectus and any
related free writing prospectus, including the section titled &#8220;Risk Factors&#8221; contained in this prospectus supplement and in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024
and our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31, 2025, June&nbsp;30, 2025 and September 30, 2025, as well as the information included in any free writing prospectus that we have
authorized for use in connection with this offering. You should also carefully read the information incorporated by reference into this prospectus supplement and the accompanying prospectus, including our consolidated financial statements, and the
exhibits to the registration statement of which this prospectus supplement and the accompanying prospectus are a part. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation targeted therapies for breast
cancer and beyond. We are advancing our pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. We aspire to transform the treatment paradigm for
metastatic breast cancer (&#8220;MBC&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead product candidate, palazestrant <FONT STYLE="white-space:nowrap">(&#8220;OP-1250&#8221;),</FONT>
is a novel, orally-available small molecule with dual activity as both a complete estrogen receptor (&#8220;ER&#8221;) antagonist (&#8220;CERAN&#8221;) and selective ER degrader (&#8220;SERD&#8221;), currently being investigated in patients with
recurrent, locally advanced or metastatic ER positive (&#8220;ER+&#8221;), human epidermal growth factor receptor 2 negative (&#8220;HER2-&#8221;) breast cancer. In <FONT STYLE="white-space:nowrap">non-clinical</FONT> models, palazestrant binds and
completely blocks <FONT STYLE="white-space:nowrap">ER-driven</FONT> transcriptional activity in both wild-type and mutant forms of ER+ MBC. In clinical studies across more than 400 patients, palazestrant has demonstrated strong anti-tumor activity,
attractive pharmacokinetics and prolonged drug exposure, favorable tolerability, and combinability with CDK4/6 inhibitors (&#8220;CDK4/6i&#8221;) with no significant drug-drug interaction. Based on the clinical results we have achieved to date, we
are advancing palazestrant through late-stage clinical development both as a monotherapy and in combination with other targeted agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our pivotal Phase
3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- MBC <FONT STYLE="white-space:nowrap">(&#8220;OPERA-01&#8221;)</FONT> is ongoing. 90 mg of once-daily palazestrant has been selected as the dose for Part 2 of <FONT
STYLE="white-space:nowrap">OPERA-01.</FONT> We anticipate <FONT STYLE="white-space:nowrap">top-line</FONT> results for this trial in the second half of 2026, expect to submit the New Drug Application in 2027, and, if successful, anticipate U.S. Food
and Drug Administration (&#8220;FDA&#8221;) approval and commercial launch in late 2027. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In combination, we are investigating palazestrant in multiple
Phase 1/2 studies with CDK4/6i (palbociclib or ribociclib), a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">phosphatidylinositol-3-kinase</FONT></FONT> alpha inhibitor (alpelisib), with an mTOR inhibitor (everolimus). We have
also entered into a clinical trial collaboration and supply agreement with Pfizer Inc. (&#8220;Pfizer&#8221;) to evaluate the safety and combinability of palazestrant and atirmociclib, Pfizer&#8217;s investigative selective CDK4 inhibitor, in
patients with ER+/HER2- MBC. We expect to initiate this Phase 1b/2 study in the fourth quarter of 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We presented updated results from the ongoing
Phase 1b/2 study of palazestrant in combination with ribociclib in patients with ER+/HER2- advanced or MBC in December 2024. In March 2025, we disclosed updated median progression-free survival (&#8220;mPFS&#8221;) data from this study. As of a data
cutoff date of February&nbsp;18, 2025, the mPFS was 13.8 months in 56 patients treated with 120 mg of palazestrant and 600 mg of ribociclib daily. 40 of the 56&nbsp;patients had received prior treatment of a CDK4/6i plus an endocrine therapy; the
mPFS in this population was 13.1 months. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2025, we presented updated data from this study. As of the data cutoff date of July 8, 2025, in
the 120&nbsp;mg palazestrant dose cohort, with a median follow-up of more than 19 months, mPFS are mature. mPFS was 15.5 months for all patients and 12.2 months for those who received prior treatment with CDK4/6i, including 9.2&nbsp;months for
patients with estrogen receptor 1 (&#8220;ESR1&#8221;) wild-type tumors and 13.8 months for patients with tumors with ESR1 mutations. In the 90 mg palazestrant dose cohort, with a median follow-up of 10.8 months, mPFS was not reached. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have initiated patient enrollment in <FONT STYLE="white-space:nowrap">OPERA-02,</FONT> the pivotal Phase 3 clinical trial of 90 mg of once-daily
palazestrant in combination with 600 mg of ribociclib daily in frontline ER+/HER2- MBC. The execution of <FONT STYLE="white-space:nowrap">OPERA-02</FONT> is supported by our clinical trial collaboration and supply agreement with Novartis Pharma AG
(collectively, with affiliated entities, &#8220;Novartis&#8221;), entered into in November 2024 (&#8220;Novartis Pharma Agreement&#8221;). Under the terms of the Novartis Pharma Agreement, Novartis will provide us with ribociclib drug supply for <FONT
STYLE="white-space:nowrap">OPERA-02.</FONT> We expect <FONT STYLE="white-space:nowrap">top-line</FONT> data in 2028 and, if successful, anticipate potential FDA approval and commercial launch in the frontline MBC setting in the U.S. in 2029. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our second product candidate in clinical development, called <FONT STYLE="white-space:nowrap">OP-3136,</FONT> is a novel, orally-available small molecule that
potently and selectively inhibits KAT6, an epigenetic target that is dysregulated in breast and other cancers. The IND application for <FONT STYLE="white-space:nowrap">OP-3136</FONT> was cleared by the FDA in late 2024 and the Phase 1 study is now
enrolling patients. In April 2025, we presented new preclinical data demonstrating the anti-tumor activity of <FONT STYLE="white-space:nowrap">OP-3136</FONT> in prostate, ovarian, and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung
cancer models. We expect initial clinical results from the <FONT STYLE="white-space:nowrap">OP-3136</FONT> Phase 1 study in mid-2026, potential additional data readout in 2027, and potential initiation of a Phase 3 clinical trial in 2028. Based on
our internal estimates, we believe that the current global market potential for <FONT STYLE="white-space:nowrap">OP-3136</FONT> in the second/third-line ER+/HER2- MBC market is approximately $5.0&nbsp;billion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination of ATM Prospectus </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with
this proposed public offering, we terminated the prospectus (the &#8220;ATM Prospectus&#8221;), filed with the registration statement of which this prospectus supplement forms a part and related to our common stock issuable pursuant to the terms of
a Sales Agreement, dated January&nbsp;6, 2025, by and between the Company and TD Securities (USA) LLC (the &#8220;Sales Agreement&#8221;). Further, we will not make any sales of our common stock pursuant to the Sales Agreement, unless and until a
new prospectus, prospectus supplement or a new registration statement is filed. Other than the termination of the ATM Prospectus, the Sales Agreement remains in full force and effect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were initially incorporated in
Delaware in August 2006 under the name CombiThera, Inc., and we commenced operations in March 2007. In March 2009, we changed our name to Olema Pharmaceuticals, Inc. Our principal executive offices are located at 780 Brannan Street, San Francisco,
California 94103, and our telephone number is <FONT STYLE="white-space:nowrap">(415)&nbsp;651-3316.&nbsp;Our</FONT> website address is www.olema.com. Information contained in, or accessible through, our website is not a part of this prospectus
supplement, and the inclusion of our website address in this prospectus supplement is only an inactive textual reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We use the Olema Oncology logo
and other marks as trademarks in the United States and other countries. This prospectus supplement contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names
referred to in this prospectus supplement, including logos, artwork and other visual displays, may appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or TM symbols, but such references are not intended to indicate in any
way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks or
service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. Smaller reporting companies may take advantage of certain scaled disclosures,
including, among other things, providing only two years of audited financial statements in their Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,&nbsp;not</FONT> being required to comply with the auditor attestation requirements of
Section&nbsp;404 of the Sarbanes-Oxley Act and having reduced disclosure obligations regarding executive compensation. We will be able to take advantage of these reduced disclosures for so long as our voting
<FONT STYLE="white-space:nowrap">and&nbsp;non-voting&nbsp;common</FONT> stock held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;is</FONT> less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter,
or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and our voting <FONT STYLE="white-space:nowrap">and&nbsp;non-voting&nbsp;common</FONT> stock held
<FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;is</FONT> less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common Stock Offered by Us</B> </P></TD>
<TD>&#8195;&#8195;&#8195;&#8195;&#8195; shares of our common stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants Offered by Us</B> </P></TD>
<TD><FONT STYLE="white-space:nowrap">Pre-funded</FONT> warrants to purchase up to&#8195;&#8195;&#8195;&#8195; shares of our common stock. Each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will have an initial exercise price per share
of&nbsp;$0.0001, subject to certain adjustments. The purchase price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant is equal to the price at which the share of our common stock is being sold in this offering, minus $0.0001. The <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercisable immediately and may be exercised at any time until all of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercised in full. For more information, see the
section titled &#8220;Description of the Securities We Are <FONT STYLE="white-space:nowrap">Offering&#8212;Pre-Funded</FONT> Warrants&#8221; on page <FONT STYLE="white-space:nowrap">S-13</FONT> of this prospectus supplement. This prospectus
supplement also relates to the offering of the shares of our common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares</B> </P></TD>
<TD>We have granted the underwriters an option to purchase up to &#8195;&#8195;&#8195;&#8195;&#8195; additional shares of our common stock. This option is exercisable, in whole or in part, for a period of 30 days following the date of this
prospectus supplement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common Stock to be Outstanding Immediately After this Offering</B> </P></TD>
<TD>&#8195;&#8195;&#8195;&#8195;shares of our common stock (or&#8195;&#8195;&#8195;&#8195;shares if the underwriters exercise their option to purchase additional shares in full), in each case, assuming no exercise of any <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants offered and sold by us. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds</B> </P></TD>
<TD>We estimate that our net proceeds from this offering will be approximately $&#8195;&#8195;&#8195;&#8195;million, or approximately $&#8195;&#8195;&#8195;&#8195;million if the underwriters&#8217; option to purchase additional shares of our common
stock from us is exercised in full, in each case, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to fund the continued clinical development of palazestrant and <FONT
STYLE="white-space:nowrap">OP-3136,</FONT> and the remainder for working capital and general corporate purposes. See &#8220;Use of Proceeds&#8221; for additional information. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk Factors</B>&#8195; </P></TD>
<TD>See &#8220;Risk Factors&#8221; beginning on page <FONT STYLE="white-space:nowrap">S-6</FONT> of this prospectus supplement and other information included and incorporated by reference in this prospectus supplement and the accompanying prospectus
for a discussion of factors that you should carefully consider before deciding to invest in our securities. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market Symbol</B> </P></TD>
<TD>Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;OLMA.&#8221; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">There is no established public trading market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and we do not expect a market to develop. In addition, we do not intend to apply for listing of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants on the Nasdaq Global Select Market, any securities exchange or recognized trading system. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding immediately after this offering set forth above is based on 68,652,730 shares of our common stock
outstanding as of September 30, 2025. Unless otherwise noted, this number excludes the shares of common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants offered hereby, and also excludes, as of
September 30, 2025, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">17,094,163 shares of common stock issuable upon the exercise of warrants with an exercise price of $0.0001 per
share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15,486,430 shares of common stock issuable upon the exercise of outstanding stock options with a weighted-average
exercise price of $8.66 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">225,600 shares of common stock issuable upon the exercise of outstanding stock options granted subsequent to
September&nbsp;30, 2025 with a weighted-average exercise price of $9.31 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,859,954 shares of common stock reserved for issuance under our 2020 Equity Incentive Plan (&#8220;2020
Plan&#8221;), and any future increase in shares reserved for issuance under such plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,647,028 shares of common stock reserved for issuance under our 2022 Inducement Plan (&#8220;Inducement
Plan&#8221;), and any future increase in shares reserved for issuance under such plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,659,132 shares of common stock reserved for issuance under our 2020 Employee Stock Purchase Plan
(&#8220;ESPP&#8221;), and any future increase in shares reserved for issuance under such plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all
information in this prospectus supplement assumes no exercise by the underwriters of their option to purchase up to &#8195;&#8195;&#8195; additional shares of our common stock, no exercise of
<FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants</FONT> that we are offering in lieu of shares of our common stock to certain investors in this offering and no exercise of the outstanding stock options or warrants summarized above.
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc846460_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks described below
and in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as updated or superseded by the risks and uncertainties described in our subsequent
filings under the Exchange Act, each of which is incorporated by reference into this prospectus supplement and the accompanying prospectus, and all of the other information in this prospectus supplement and the accompanying prospectus, including our
consolidated financial statements and related notes incorporated by reference in this prospectus supplement and the accompanying prospectus. If any of these risks is realized, our business, financial condition, results of operations and prospects
could be harmed. In that event, the trading price of our securities could decline, and you could lose part or all of your investment. Additional risks and uncertainties that are not yet identified or that we think are immaterial may also harm our
business, operating results and financial condition and could result in a complete loss of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our management team will have broad discretion to use the net proceeds from this offering, and its investment of these proceeds may not yield a
favorable return. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management team will have broad discretion in the application of the net proceeds from this offering and could spend or
invest the proceeds in ways with which our stockholders disagree. Accordingly, investors will need to rely on our management team&#8217;s judgment with respect to the use of these proceeds. We intend to use the proceeds from this offering in the
manner described in the section titled &#8220;Use of Proceeds.&#8221; The failure by management to apply these funds effectively could negatively affect our ability to operate and grow our business. We cannot specify with certainty all of the
particular uses for the net proceeds to be received upon the completion of this offering. In addition, the amount, allocation and timing of our actual expenditures will depend upon numerous factors, including any milestone payments received or paid
in connection with any future strategic partnerships and royalties on sales of any future approved product. Accordingly, we will have broad discretion in using these proceeds. Until the net proceeds are used, they may be placed in investments that
do not produce significant income or that may lose value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our current operating plans, we believe our existing cash, cash equivalents and
marketable securities and the funds available to us under our Loan and Security Agreement, dated September&nbsp;5, 2023, as amended, with Silicon Valley Bank, a division of First Citizens Bank &amp; Trust Company (the &#8220;Loan and Security
Agreement&#8221;), together with the net proceeds from this offering, will be sufficient to fund our projected operating requirements into 2028, which include the potential U.S. commercial launch of palazestrant, which, if our trials are successful
and we receive FDA approval, we expect to occur in late 2027. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. We cannot predict with any
certainty the timing or availability of additional funds under the Loan and Security Agreement, if at all. We will require substantial additional funding to develop our product candidates and support our continuing operations beyond our current
operating plans. If adequate funds are not available on a timely basis, if at all, we may be unable to pursue further development or potential commercialization of palazestrant which would significantly harm our business, prospects, financial
condition and results of operations and cause the price of our common stock to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase securities in this offering, you will
experience immediate and substantial dilution of your investment. You will experience further dilution if we issue additional equity securities in future fundraising transactions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The price of our common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in this offering may be higher than the net tangible book value
per share of our common stock. Therefore, if you purchase securities in this offering, you may pay a price per share (or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant at the offering price less $0.0001) that substantially exceeds our
net tangible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
book value per share. Based on the public offering price of $&#8195;&#8195;&#8195;&#8195;per share (or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant at the offering price less
$0.0001), our as adjusted net tangible book value as of September&nbsp;30, 2025 would have been $&#8195;&#8195;&#8195;&#8195;million, or $&#8195;&#8195;&#8195;&#8195;per share, representing an immediate increase in the net tangible book value per
share of $&#8195;&#8195;&#8195;&#8195;to existing stockholders and an immediate dilution of $&#8195;&#8195;&#8195;&#8195;in net tangible book value per share to investors purchasing securities in this offering, representing the difference between
our as adjusted net tangible book value per share after giving effect to this offering and the public offering price. The foregoing assumes that the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants issued in connection with this offering
are not exercised. To the extent outstanding stock options or warrants are exercised, there will be further dilution to new investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we issue
additional common stock, or securities convertible into or exchangeable or exercisable for common stock, including shares issuable upon the potential exercise of currently outstanding warrants, our stockholders, including investors who purchase our
securities in this offering, will experience additional dilution, and any such issuances may cause the price of our common stock to decrease. We also cannot assure you that we will be able to sell shares or other securities in any other offering at
a price per share that is equal to or greater than either the price per share of common stock (or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant) paid by investors in this offering, and investors purchasing shares or other securities in
the future could have rights superior to investors in this offering. See &#8220;Dilution&#8221; for a more detailed description of the dilution to new investors in the offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividend on our capital stock. We currently anticipate that we will retain future earnings for the development,
operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of our Loan and Security Agreement place certain limitations on our ability to pay cash dividends
without the consent of the Bank. Any return to stockholders will therefore be limited to the appreciation of their stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not sustain an
active trading market for our common stock, and you may not be able to resell your shares of our common stock at or above the offering price, if at all. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The public offering price for our common stock will be determined through negotiations between us and the underwriters and may not be indicative of the price
at which our common stock will trade after the closing of this offering. Although our common stock has been listed on the Nasdaq Global Select Market since November&nbsp;19, 2020, an active trading market for our shares may not be sustained in the
future. If an active market for our common stock is not sustained, it may be difficult for you to sell shares you purchased in this offering at an attractive price or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, certain existing stockholders of our company and their affiliates may purchase shares of common stock being sold by us in this offering at the
public offering price and on the same terms as the other shares of common stock being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This concentration of ownership by our existing
stockholders may result in fewer shares being actively traded in the public market because these stockholders may be restricted from selling such shares under applicable securities laws, which could reduce the liquidity of the market and the
available public float for our shares of common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are not listed on any
exchange and we do not intend to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on any exchange. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you purchase <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, you may be unable to sell such warrants at the prices desired or at all. There is no existing trading market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and there can be
no assurance that a liquid market will develop or be maintained for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, or that you will be able to sell any of the <FONT STYLE="white-space:nowrap">pre-funded</FONT>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
warrants at a particular time (if at all). In addition, we do not intend to apply for listing of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on the Nasdaq Global Select Market
or any other securities exchange or nationally recognized trading system. The liquidity of the trading market in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and the sale price, if any, for the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, may be adversely affected by, among other things: (i)&nbsp;changes in the overall market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants; (ii)&nbsp;changes in our
financial performance or prospects; (iii)&nbsp;changes or perceived changes in our creditworthiness; (iv)&nbsp;the prospects for companies in the industry generally; (v)&nbsp;the number of holders of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants; and (vi)&nbsp;the interest of securities dealers in making a market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holders of the <FONT STYLE="white-space:nowrap">pre-funded&nbsp;warrants</FONT> will have no rights as common stockholders until such holders exercise
their <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and acquire our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until you acquire shares of our common stock upon
exercise of the <FONT STYLE="white-space:nowrap">pre-funded&nbsp;warrants,</FONT> you will have no rights with respect to our common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded&nbsp;warrants,</FONT> including the
right to receive dividend payments, vote or respond to tender offers. Upon exercise of your <FONT STYLE="white-space:nowrap">pre-funded&nbsp;warrants,</FONT> you will be entitled to exercise the rights of a common stockholder only as to matters for
which the record date occurs after the exercise date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant holders or beneficial owners of our common stock may not be permitted to exercise
<FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants</FONT> that they hold. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder (together with its affiliates and other
attribution parties) may not exercise any portion of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant to the extent that immediately prior to or after giving effect to such exercise the holder would beneficially own more than 9.99% of
our outstanding common stock immediately after exercise, which percentage may be changed at the holder&#8217;s election to a higher or lower percentage not in excess of 19.99% (if exceeding such percentage would result in a change of control under
Nasdaq Listing Rule 5635(b) or any successor rule) upon 61 days&#8217; notice to us subject to the terms of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. As a result, you may not be able to exercise your <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants for shares of our common stock at a time when it would be financially beneficial for you to do so. In such a circumstance, you could seek to sell your
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to realize value, but you may be unable to do so in the absence of an established trading market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and due to applicable
transfer restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not maintain a current and effective registration statement relating to the shares of our common stock issuable
upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded&nbsp;warrants,</FONT> holders will only be able to exercise such <FONT STYLE="white-space:nowrap">pre-funded&nbsp;warrants</FONT> on a &#8220;cashless basis.&#8221; </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we do not maintain a current and effective registration statement relating to the shares of our common stock issuable upon exercise of the <FONT
STYLE="white-space:nowrap">pre-funded&nbsp;warrants</FONT> at the time that holders wish to exercise such <FONT STYLE="white-space:nowrap">pre-funded&nbsp;warrants,</FONT> they will only be able to exercise them on a &#8220;cashless basis&#8221;
provided that an exemption from registration is available. As a result, the number of shares of our common stock that holders will receive upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded&nbsp;warrants</FONT> will be fewer than it
would have been had such holder exercised such <FONT STYLE="white-space:nowrap">pre-funded&nbsp;warrants</FONT> for cash, and holders may be limited in their ability to immediately sell shares upon exercise subject to volume or other securities law
limitations. Further, if an exemption from registration is not available, holders would not be able to exercise on a cashless basis and would only be able to exercise their <FONT STYLE="white-space:nowrap">pre-funded&nbsp;warrants</FONT> for cash if
a current and effective registration statement relating to the shares of our common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded&nbsp;warrants</FONT> is available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc846460_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and accompanying prospectus, including the information incorporated by reference herein and therein, contain forward-looking
statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&nbsp;21E of the Exchange Act, and the Private Securities Litigation Reform Act of 1995, as amended, that
involve substantial risks and uncertainties. All statements contained in this prospectus supplement and accompanying prospectus regarding future events, results or outcomes, including our future results of operations and financial position, business
strategy, research and development costs, the anticipated timing, costs and conduct of our planned clinical trials for our product candidates, the timing and likelihood of regulatory filings and approvals for our product candidates, our ability to
commercialize our product candidates, if approved, the pricing and reimbursement of our product candidates, if approved, the potential benefits of strategic collaborations and our ability to enter into strategic arrangements, timing and likelihood
of success, plans and objectives of management for future operations, and future results of anticipated products are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may
cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. This prospectus supplement, the accompanying prospectus and
the documents incorporated by reference herein and therein also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of
assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are
necessarily subject to a high degree of uncertainty and risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as
&#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplates,&#8221;
&#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this prospectus supplement and
accompanying prospectus are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition
and results of operations. These forward-looking statements speak only as of the date of this prospectus supplement, the accompanying prospectus or the documents incorporated by reference in this prospectus supplement, as applicable, and are subject
to a number of risks, uncertainties and assumptions described under the sections in this prospectus supplement, accompanying prospectus and the documents incorporated by reference herein under the captions &#8220;Risk Factors&#8221; and
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and elsewhere in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of
future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an
evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we undertake no obligation to publicly
update or revise any forward-looking statements contained or incorporated by reference herein, whether as a result of any new information, future events, changed circumstances or otherwise. You should, however, review the factors and risks we
describe in the reports we will file from time to time with the SEC after the date of this prospectus supplement. See &#8220;Where You Can Find More Information.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are
based on information available to us as of the date of this prospectus supplement, and the accompanying prospectus or the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, as applicable, and while we
believe such information provides a reasonable basis for these statements, and our management is responsible for the accuracy of such statements, such information may be limited or incomplete. These statements are inherently uncertain, and you are
cautioned not to unduly rely on these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc846460_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from our issuance and sale of shares of our common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to
purchase&#8195;&#8195;&#8195;&#8195;shares of common stock in this offering will be approximately $&#8195;&#8195;&#8195;&#8195;million, or approximately $&#8195;&#8195;&#8195;&#8195;million if the underwriters exercise their option to purchase
additional shares of our common stock in full, in each case, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We will receive nominal proceeds, if any, from any exercise of <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds from this offering, together with our existing cash,
cash equivalents and marketable securities, to fund the continued clinical development of palazestrant and <FONT STYLE="white-space:nowrap">OP-3136,</FONT> and the remainder for working capital and general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our current operating plans, we believe our existing cash, cash equivalents and marketable securities and the funds available to us under our Loan
and Security Agreement with the Bank, together with the net proceeds from this offering, will be sufficient to fund our projected operating requirements into &#8195;&#8195;&#8195;&#8195;, which include the potential U.S. commercial launch of
palazestrant, which, if our trials are successful and we receive FDA approval, we expect to occur in late 2027. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we
currently expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also use a portion of the net proceeds to acquire or invest in businesses and products that are complementary to our own,
although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus supplement. Pending the use of net proceeds, we intend to invest the net proceeds in short-term, investment-grade,
interest bearing instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts and timing of our actual expenditures will depend on numerous factors, including the time and cost necessary to
conduct our planned clinical trials, the results of our planned clinical trials and other factors described in the section titled &#8220;Risk Factors&#8221; in this prospectus supplement and the accompanying prospectus, including the information
incorporated by reference herein and therein, as well as the amount of cash used in our operations and any unforeseen cash needs. Therefore, our actual expenditures may differ materially from the estimates described above. We may find it necessary
or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc846460_6"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2025, we had a net tangible book value of $307.5&nbsp;million, or $4.48&nbsp;per share of common stock, based on 68,652,730 shares of
common stock outstanding as of such date. Our historical net tangible book value per share represents total tangible assets less total liabilities, divided by the number of shares of common stock outstanding at September&nbsp;30, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to the sale by us of (i) &#8195; shares of common stock and <FONT STYLE="white-space:nowrap">(ii)&nbsp;pre-funded</FONT> warrants to
purchase &#8195;&#8195;&#8195;&#8195; shares of our common stock in this offering at the public offering price of $&#8195;&#8195;&#8195;&#8195;per share and $&#8195;&#8195;&#8195;&#8195;per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant,
which equals the offering price per share of the common stock less the $0.0001 per share exercise price of each such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant (and excluding shares of common stock issued upon the exercise of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants or any resulting accounting associated with <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants),</FONT> and after deducting underwriting discounts and commissions and estimated
offering expenses payable by us, our as adjusted net tangible book value as of September&nbsp;30, 2025 would have been approximately $&#8195;&#8195;&#8195;&#8195;million, or approximately $&#8195;&#8195;&#8195;&#8195;per share. This amount
represents an immediate increase in our net tangible book value of approximately $&#8195;&#8195;&#8195;&#8195;per share to our existing stockholders and an immediate dilution in our net tangible book value of approximately
$&#8195;&#8195;&#8195;&#8195;per share to investors purchasing common stock in this offering. We determine dilution by subtracting our as adjusted net tangible book value per share after this offering from the amount of cash paid by an investor for
a share of common stock in this offering. The following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share as of September&nbsp;30, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to investors purchasing shares in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after giving effect to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in net tangible book value per share to investors purchasing shares in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If holders of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants offered in this offering exercise in full the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, the as adjusted net tangible book value per share after giving effect to this offering would be $&#8195;&#8195;&#8195; per share, representing an immediate increase in our net tangible book
value of approximately $&#8195;&#8195;&#8195;per share to our existing stockholders and an immediate dilution in our net tangible book value of approximately $&#8195;&#8195;&#8195; per share to new investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the underwriters exercise in full their option to purchase up to&#8195;&#8195;&#8195;&#8195;additional shares of common stock at the public offering price
of $&#8195;&#8195;&#8195;&#8195;per share, the as adjusted net tangible book value per share after this offering would be approximately $&#8195;&#8195;&#8195;&#8195;, representing an increase in net tangible book value of approximately
$&#8195;&#8195;&#8195;&#8195;per share to our existing stockholders and immediate dilution in net tangible book value of approximately $&#8195;&#8195;&#8195;&#8195; per share to new investors purchasing our common stock in this offering at the
public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors who purchase common stock upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants offered
hereby may experience dilution depending on our net tangible book value at the time of exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above table and calculations (other than net
tangible book value calculations) are based 68,652,730 shares of our common stock outstanding as of September&nbsp;30, 2025. Unless otherwise noted, this number excludes the shares of common stock issuable upon exercise of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants offered hereby, and also excludes, as of September&nbsp;30, 2025, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">17,094,163 shares of common stock issuable upon the exercise of warrants with an exercise price of $0.0001 per
share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15,486,430 shares of common stock issuable upon the exercise of outstanding stock options with a weighted-average
exercise price of $8.66 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">225,600 shares of common stock issuable upon the exercise of outstanding stock options granted subsequent to
September&nbsp;30, 2025 with a weighted-average exercise price of $9.31 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,859,954 shares of common stock reserved for issuance under our 2020 Plan, and any future increase in shares
reserved for issuance under such plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,647,028 shares of common stock reserved for issuance under our Inducement Plan, and any future increase in
shares reserved for issuance under such plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,659,132 shares of common stock reserved for issuance under our ESPP, and any future increase in shares reserved
for issuance under such plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that any outstanding options or warrants are exercised or new options or restricted stock
units are issued under our stock-based compensation plans, or we issue additional shares of common stock in the future, there will be further dilution to investors participating in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc846460_7"></A>DESCRIPTION OF THE SECURITIES WE ARE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering &#8195;&#8195;&#8195; shares of our common stock, or for certain investors that so choose, in lieu of shares of common <FONT
STYLE="white-space:nowrap">stock,&nbsp;pre-funded&nbsp;warrants</FONT> to purchase &#8195;&#8195;&#8195;shares of our common stock, or <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants.</FONT> The common stock and <FONT
STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants</FONT> will be sold at the same time. The shares of common stock issuable from time to time upon exercise of <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants,</FONT> if
any, are also being offered pursuant to this prospectus supplement and the accompanying prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus supplement, our amended and restated certificate of incorporation authorizes us to issue 490,000,000 shares of common stock,
par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001per share. The holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. Except as
otherwise expressly provided in our amended and restated certificate of incorporation or required by applicable law, all shares of common stock will have the same rights and privileges and rank equally, share ratably, and be identical in all
respects for all matters, including the following dividend and liquidation rights. Subject to preferences that may be applicable to any outstanding shares of the preferred stock, the holders of common stock are entitled to receive ratably such
dividends as may be declared by the board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders of our common stock are entitled to share equally, identically, and ratably in all assets remaining after
payment of liabilities, the liquidation preferences of any outstanding shares of preferred stock legally available for distribution to stockholders. Holders of common stock have no preemptive rights and no right to convert their common stock into
any other securities. There are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the
holders of shares of any series of preferred stock which we may designate in the future. For more information, see &#8220;Description of Capital Stock&#8221; in Exhibit 4.3 to our Annual Report on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the year ended December&nbsp;31, 2021, which Exhibit 4.3 is incorporated by reference into this prospectus supplement and the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;OLMA.&#8221; The transfer agent and registrar for our common stock is
Computershare Trust Company, N.A. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The material terms and provisions of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being issued in this offering are summarized below. The
following description is subject to, and qualified in its entirety by, the form of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant which will be filed as an exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT>
to be filed by us with the SEC in connection with this offering. You should review the form of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant for a complete description of the terms and conditions applicable to the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. See &#8220;Where You Can Find More Information&#8221; on page <FONT STYLE="white-space:nowrap">S-30</FONT> of this prospectus supplement. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exercisability</I>. The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be immediately exercisable, at the option of each holder, in whole
or in part, and may be exercised at any time until the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercised in full. A holder may exercise the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants by delivering to us a
duly executed exercise notice and by payment in full of the exercise price for the number of shares of common stock purchased upon such exercise. The exercise price must be paid by the holder in cash in immediately available funds. The holder may
also exercise the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant through a &#8220;cashless exercise,&#8221; in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the
formula set forth in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exercise Limitations</I>. A holder (together with its affiliates
and other attribution parties) may not exercise any portion of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant to the extent that, immediately prior to or after giving effect to such exercise, the holder would beneficially own more than
9.99% of our outstanding common stock after giving effect to such exercise, which percentage may be increased or decreased at the holder&#8217;s election to a percentage not in excess of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
19.99% (if exceeding such percentage would result in a change of control under Nasdaq Listing Rule 5635(b) or any successor rule) upon 61 days&#8217; notice to us subject to the terms of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exercise Price</I>. Each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant offered
hereby has an initial exercise price per share equal to $0.0001. The exercise price and number of shares of common stock issuable upon exercise is subject to adjustment in the event of stock dividends and distributions, stock splits, stock
combinations, reclassifications or similar events affecting our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>. Subject to compliance with any applicable
securities laws, the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are separately tradeable immediately after issuance and may be transferred at the option of the holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>No Listing</I>. There is no established public trading market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and we do not expect a
market to develop. In addition, we do not intend to apply for listing of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on any securities exchange or recognized trading system, including the Nasdaq Global Select Market. Without an
active market, the liquidity of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fundamental Transactions</I>. In the
event of a fundamental transaction, as described in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other
disposition of all or a majority of our properties or assets on a consolidated basis, our consolidation or merger with or into another person in which we are not the surviving entity, the acquisition of more than 50% of our outstanding common stock,
or any person or group becoming the beneficial owner of more than 50% of the voting power represented by our outstanding common stock, the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be deemed fully exercised immediately prior
to the consummation of such fundamental transaction without regard to any limitations on exercise contained in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants pursuant to the &#8220;cashless exercise&#8221; provision in the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, and after the completion of such full exercise, shall be deemed terminated upon the consummation of such fundamental transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rights as a Stockholder</I>. Except for the right to participate in certain dividends and distributions and as otherwise provided in the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants or by virtue of a holder&#8217;s ownership of shares of our common stock, the holders of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants do not have the rights or privileges of
holders of our common stock, including any voting rights, until they exercise their <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Warrant Agent</I>. We are acting as warrant agent for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc846460_8"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of certain material U.S. federal income tax consequences to U.S. holders and <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holders (each as defined below, and, collectively, &#8220;holders&#8221;) of the acquisition, ownership and disposition of our common stock <FONT STYLE="white-space:nowrap">and&nbsp;pre-funded&nbsp;warrants</FONT> offered pursuant to this prospectus
supplement. This discussion is not a complete analysis of all potential U.S. federal income tax consequences relating thereto, does not address the potential application of the Medicare contribution tax on net investment income, any alternative
minimum tax, or the special tax accounting rules under Section&nbsp;451(b) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and does not address any U.S.
<FONT STYLE="white-space:nowrap">federal&nbsp;non-income&nbsp;tax</FONT> consequences such as estate or gift tax consequences or any tax consequences arising under any state, local, <FONT STYLE="white-space:nowrap">or&nbsp;non-U.S.&nbsp;tax</FONT>
laws. This discussion is based on the Code and applicable Treasury Regulations promulgated thereunder, published rulings, administrative pronouncements of the Internal Revenue Service (the &#8220;IRS&#8221;) and judicial decisions, all as in effect
as of the date hereof. These authorities are subject to differing interpretations and may change, possibly retroactively, resulting in U.S. federal income tax consequences different from those discussed below. We have not requested a ruling from the
IRS with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion is limited to holders that purchase our common stock <FONT STYLE="white-space:nowrap">or&nbsp;pre-funded&nbsp;warrants</FONT> offered by this
prospectus supplement and that hold our common stock <FONT STYLE="white-space:nowrap">or&nbsp;pre-funded&nbsp;warrants</FONT> as a &#8220;capital asset&#8221; within the meaning of Section&nbsp;1221 of the Code (generally, property held for
investment). This discussion does not address all of the U.S. federal income tax consequences that may be relevant to a particular holder in light of such holder&#8217;s particular circumstances. This discussion also does not consider any specific
facts or circumstances that may be relevant to holders subject to special rules under the U.S. federal income tax laws, including, without limitation:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other entities or arrangements treated as partnerships, S corporations or other pass-through
entities, or disregarded entities, for U.S. federal income tax purposes (and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;controlled foreign corporations&#8221;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;passive foreign investment companies&#8221;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts or regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, financial institutions, investment funds, insurance companies, or brokers or dealers in securities or
currencies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that have elected to mark securities to market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations and governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquired our common stock through the exercise of employee stock options or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants as
&#8220;qualified small business stock&#8221; under Section&nbsp;1202 of the Code, or &#8220;Section&nbsp;1244 stock&#8221; under Section&nbsp;1244 of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that acquired our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in a
transaction subject to the gain rollover provisions of the Code (including Section&nbsp;1045 of the Code); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants under the
constructive sale provisions of the Code; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own, or have owned, actually or constructively, more than 5% of our common stock, including, for
this purpose, our <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. persons whose &#8220;functional currency&#8221; is not the United States dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;qualified foreign pension funds&#8221; as defined in Section&nbsp;897(l)(2) of the Code and entities all
of the interests of which are held by qualified foreign pension funds; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants as part of a
hedging or conversion transaction or straddle, or other risk reduction strategy or integrated investment. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an entity or arrangement
that is classified as a partnership for U.S. federal income tax purposes holds our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, the U.S. federal income tax treatment of a partner in the partnership generally will
depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Partnerships holding our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and the partners in
such partnerships are urged to consult their tax advisors about the particular U.S. federal income tax consequences to them of acquiring, owning and disposing of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR
U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING, AND DISPOSING OF OUR COMMON STOCK OR <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, OR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> TAX LAWS, ANY U.S. FEDERAL <FONT STYLE="white-space:nowrap">NON-INCOME</FONT> TAX LAWS, OR ANY APPLICABLE INCOME TAX TREATY. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#8220;U.S. holder&#8221; is any beneficial owner of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants that is a &#8220;U.S. person&#8221; (as defined below) and is not a partnership (including any entity or arrangement treated as a partnership) for U.S. federal income tax purposes. A &#8220;U.S. person&#8221; is any person that, for U.S.
federal income tax purposes, is or is treated as any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (or any other entity treated as a corporation for U.S. federal income tax purposes) created or
organized under the laws of the United States, any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (1)&nbsp;the administration of which is subject to the primary supervision of a U.S. court and that has
one or more United States persons (within the meaning of Section&nbsp;7701(a)(30) of the Code) with the authority to control all substantial decisions of the trust or (2)&nbsp;that has a valid election in effect under applicable Treasury Regulations
to be treated as a United States person. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#8220;non-U.S.</FONT>
holder&#8221; is a beneficial owner of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants that is neither a U.S. person nor a partnership (including any entity or arrangement treated as a partnership) for U.S. federal
income tax purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Characterization of Our <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants for Tax Purposes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the characterization of our <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants for U.S. federal income tax purposes is not entirely clear,
because the exercise price of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is a nominal amount, we expect to treat the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants as our common stock for U.S. federal income tax
purposes. Accordingly, no gain or loss should be recognized upon the exercise of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant (other than with respect to any cash paid in lieu of a fractional share) and, upon exercise, the holding
period of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant should carry over to the share received. Similarly, the tax basis of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant should carry over to the share received upon
exercise, increased by the exercise price. Except where specifically noted below, the following discussion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assumes the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are treated as common stock. Some portions of the below discussion make reference to potential consequences associated with
the acquisition, ownership and disposition of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants independent of their potential characterization as our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our position with respect to the U.S. federal income tax characterization of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is not binding on
the IRS and the IRS may treat the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants as warrants to acquire our common stock for U.S. federal income tax purposes and, if so, the amount and character of a holder&#8217;s gain with respect to
an investment in our <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants could change. Holders should consult their tax advisors regarding the characterization of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants for U.S.
federal income tax purposes, and the consequences of an investment in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants based on their own particular facts and circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Consequences to U.S. Holders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions
on Our Common Stock or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our common stock,
and we do not currently intend to pay any cash dividends on our common stock in the foreseeable future. However, if we make cash or other property distributions on our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, such
distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Dividends received by certain <FONT
STYLE="white-space:nowrap">non-corporate</FONT> U.S. holders, including individuals, generally are taxed at long-term capital gains rates, provided certain holding period requirements are satisfied. Dividends received by corporate U.S. holders may
be eligible for a dividends received deduction, subject to applicable limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Distributions in excess of our current and accumulated earnings and
profits will constitute a return of capital and will first be applied against and reduce a holder&#8217;s tax basis in our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, but not below zero. Any amount distributed in
excess of basis will be treated as gain realized on the sale or other disposition of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and will be treated as described under the section titled &#8220;&#8212;Sale or
Other Disposition of Our Common Stock or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants&#8221; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The taxation of property (other than
common shares) received with respect to a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant on exercise is unclear. It is possible that such a receipt of property would be treated as a distribution on common stock as described in this
section, although other treatments also may be possible. U.S. holders should consult their tax advisors regarding the proper treatment of any such receipt of property in respect of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on
exercise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Constructive Dividends on Our <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. holder of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant may, in some circumstances, be deemed to have received a distribution subject to
U.S. federal income tax as a result of an adjustment or the <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of an adjustment to the exercise price or number of shares of our common stock issuable upon exercise of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant. U.S. holders should consult their tax advisors regarding the proper treatment of any adjustments (or the <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of any adjustments) to the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale or Other Disposition of Our Common Stock or
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For U.S. federal income tax purposes, gain or loss realized on the sale or other taxable
disposition of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants generally will be capital gain or loss, and will be long-term capital gain or loss if the U.S. holder has held the common stock or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants for more than one year. The amount of the gain or loss will equal the difference between (i)&nbsp;the amount of cash and the fair market value of any property received on the disposition and
(ii)&nbsp;such U.S. holder&#8217;s tax basis in the common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants disposed of. Long-term capital gains recognized by <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holders
generally will be subject to reduced U.S. federal income tax rates. The deductibility of capital losses is subject to limitations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information reporting requirements generally will apply to distributions (including deemed distributions) on our common stock or
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, and gross proceeds on the sale or other disposition of our common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, unless the U.S. holder is an exempt recipient (such
as certain corporations). Backup withholding (currently at a 24% rate) will apply to those payments if the U.S. holder is not otherwise exempt and fails to provide its correct taxpayer identification number or certification of exempt status on an
IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> (Request for Taxpayer Identification Number and Certification), or if the U.S. holder is notified by the IRS that it has failed to report in full payments of interest and dividend income. Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules should be allowed as a refund or a credit against a U.S. holder&#8217;s U.S. federal income tax liability provided the required information is furnished
timely to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If backup withholding is applied to a U.S. holder, the U.S. holder should consult with its own tax advisor to determine whether it has
overpaid its U.S. federal income tax, and whether it is able to obtain a tax refund or credit of the overpaid amount. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on Our Common Stock or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed above under &#8220;Tax Consequences to U.S. Holders&#8212;Distributions on Our Common Stock or
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants,&#8221; we have never declared or paid cash dividends on our common stock, and we do not currently intend to pay any cash dividends on our common stock in the foreseeable future. However,
if we make cash or other property distributions on our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current
or accumulated earnings and profits, as determined under U.S. federal income tax principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Distributions that are not treated as dividends for U.S.
federal income tax purposes will constitute a return of capital and first be applied against and reduce a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s adjusted tax basis in our common stock or
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, but not below zero. Any excess will be treated as capital gain and will be treated as described below under &#8220;&#8212;Gain on Sale or Other Disposition of Our Common Stock or <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding effectively connected income, backup
withholding, and Sections 1471 through 1474 of the Code (&#8220;FATCA&#8221;), dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants generally
will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends or such lower rate specified by an applicable income tax treaty. To receive the benefit of a reduced treaty rate, a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must furnish us or the applicable withholding agent with a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> as applicable (or other appropriate form, or applicable successor form), certifying such holder&#8217;s qualification for the reduced rate. This certification must be provided to us or the
applicable withholding agent before the payment of dividends and may need to be updated periodically. In the case of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is an entity, Treasury Regulations and the relevant tax treaty
provide rules to determine whether, for purposes of determining the applicability of the tax treaty, dividends will be treated as paid to the entity or to those holding an interest in the entity. If the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds the common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants through a financial institution or other agent acting on the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s behalf, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be required to provide appropriate documentation to the agent, which then will be required to provide
certification to us or the applicable withholding agent, either directly or through other intermediaries. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders that do not provide the required certification on a timely basis, but that qualify for
a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in connection with the conduct of a trade or business in the United States, and dividends paid on our common
stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are effectively </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connected with such holder&#8217;s U.S. trade or business (and, if required by an applicable tax treaty, are attributable to such holder&#8217;s permanent establishment or fixed base in the
United States), the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be exempt from U.S. federal withholding tax. To claim the exemption, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally must furnish a
valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or applicable successor form) to the applicable withholding agent. This certification must be provided to us or the applicable withholding agent before the payment of dividends and may
need to be updated periodically. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, any such effectively connected dividends paid on our common stock or
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants generally will be subject to U.S. federal income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United
States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively
connected dividends for the taxable year, as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules.
The taxation of property (other than common shares) received with respect to a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant on exercise is unclear. It is possible such a receipt of property would be treated as a distribution as
described in this section, although other treatments also may be possible. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the proper treatment of any such receipt of property in respect of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants on exercise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Constructive Dividends on Our <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant may, in some
circumstances, be deemed to have received a distribution subject to U.S. federal income tax as a result of an adjustment or the <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of an adjustment to the exercise price or number of shares of our
common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. Any resulting withholding tax attributable to deemed dividends may be collected from other amounts payable or distributable to the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the proper treatment of any adjustments (or the
<FONT STYLE="white-space:nowrap">non-occurrence</FONT> of any adjustments) to the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on
Sale or Other Disposition of Our Common Stock or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussions below
regarding backup withholding and FATCA, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to U.S. federal income tax on any gain realized on the sale or other taxable disposition of our common stock or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s
conduct of a trade or business in the United States and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base in the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual present in the
United States for 183 days or more during the taxable year of the disposition, and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants constitute a &#8220;United States
real property interest&#8221; by reason of our status as a &#8220;United States real property holding corporation&#8221; (&#8220;USRPHC&#8221;) for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the
disposition or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s holding period for our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular U.S. federal income
tax rates in the same manner as if such holder were a resident of the United States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may be subject to an additional branch profits tax equal to 30% (or
such lower rate specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gain described in the second bullet point above will be subject to U.S. federal income tax at a flat 30% rate (unless an applicable income tax treaty provides
for different treatment), but may be offset by certain U.S.-source </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital losses (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S.
federal income tax returns with respect to such losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to gain described in the third bullet point above, determining whether we are a
USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our other trade or business assets and our foreign real property interests. We do not believe that we are, and do not anticipate
becoming, a USRPHC for U.S. federal income tax purposes, although there can be no assurance in this regard. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will not be subject to U.S. federal income tax if our common stock is &#8220;regularly traded,&#8221; as
defined by applicable Treasury Regulations, on an established securities market such as the Nasdaq Global Select Market, and such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder owned, actually and constructively (including through ownership
of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants), 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder&#8217;s holding period. There can be no assurance that our common stock will be regularly traded on an established securities market for purposes of the rules described above. Special rules may
apply to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, who should consult their tax advisors. If we are a USRPHC during the relevant period and a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder is not exempt as described above, gain described in the third bullet above generally will be subject to U.S. federal income tax in the same manner as gain that is effectively connected with the
conduct of a U.S. trade or business, except that the branch profits tax generally will not apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and
Backup Withholding </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annual reports are required to be filed with the IRS and provided to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
indicating the amount of distributions (including deemed distributions) on our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants paid to such holder and the amount of any tax withheld with respect to those distributions.
These information reporting requirements apply even if no withholding was required (because the distributions were effectively connected with the holder&#8217;s conduct of a U.S. trade or business, or withholding was reduced or eliminated by an
applicable income tax treaty) and regardless of whether such distributions constitute dividends. This information also may be made available under a specific treaty or agreement with the tax authorities in the country in which the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is established. Backup withholding (currently at a 24% rate) generally will not apply to payments to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of dividends on or the gross
proceeds of a disposition of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants provided the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder furnishes the required certification for its <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by providing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> or IRS Form <FONT
STYLE="white-space:nowrap">W-8ECI,</FONT> as applicable, or certain other requirements are met. Backup withholding may apply if the payor has actual knowledge, or reason to know, that the holder is a U.S. person who is not an exempt recipient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. If any amount is withheld under the backup withholding rules, the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder should consult with a U.S. tax advisor regarding the possibility of and procedure for obtaining a refund or a credit against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s U.S.
federal income tax liability, if any. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withholding on Foreign Entities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FATCA imposes a U.S. federal withholding tax of 30% on certain payments made to a &#8220;foreign financial institution&#8221; (as specially defined under these
rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding certain U.S. account holders of such
institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exemption applies. FATCA also generally will impose a U.S. federal withholding tax of 30% on certain payments made to a <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity unless
such entity provides the withholding agent a certification identifying certain direct and indirect U.S. owners of the entity or an exemption applies. An intergovernmental agreement between the United States and an applicable foreign country may
modify these requirements. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for refunds or credits of such taxes. FATCA applies to dividends (including deemed dividends) paid on our common
stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and, subject to the proposed Treasury Regulations described below, also applies to gross proceeds from sales or other dispositions of our common stock or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. The U.S. Treasury Department has released proposed Treasury Regulations which, if finalized in their present form, would eliminate the federal withholding tax of 30% applicable to the gross
proceeds of a disposition of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. In the preamble to such proposed Treasury Regulations, the U.S. Treasury Department stated that taxpayers (including applicable withholding
agents) generally may rely on the proposed Treasury Regulations until final regulations are issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prospective investors are encouraged to consult with
their own tax advisors regarding the possible implications of FATCA on their investment in our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE U.S.
FEDERAL, STATE, AND LOCAL AND <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> INCOME AND <FONT STYLE="white-space:nowrap">NON-INCOME</FONT> TAX CONSEQUENCES OF ACQUIRING, OWNING, AND DISPOSING OF OUR COMMON STOCK OR
<FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS IN THEIR PARTICULAR CIRCUMSTANCES, INCLUDING RELATED REPORTING REQUIREMENTS AND THE IMPACT OF ANY POTENTIAL CHANGE IN LAW. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc846460_9"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and TD Securities (USA) LLC, as the representative of the underwriters named below, have entered into an underwriting agreement with
respect to the securities being offered. Subject to the terms and conditions of the underwriting agreement, the underwriters have agreed to purchase from us the number of shares of our common stock and
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Underwriters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR><FONT STYLE="white-space:nowrap">Pre-Funded</FONT><BR>Warrant<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TD Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting agreement provides that the obligations of the underwriters to purchase the shares and <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants included in this offering are subject to certain conditions precedent and that the underwriters have, severally and not jointly, agreed to purchase all of the shares and <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants sold under the underwriting agreement if any of these shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are purchased, other than those shares covered by the option to
purchase additional shares described below. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the non-defaulting underwriters may be increased or the underwriting agreement may be terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act of 1933, and to
contribute to payments the underwriters may be required to make in respect thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares and <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other conditions specified in the underwriting agreement. The
underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Option to
Purchase Additional Shares. </I>We have granted the underwriters an option to purchase up to &#8195; additional shares of common stock at the public offering price, less the underwriting discounts and commissions. This option is exercisable for a
period of 30 days. To the extent that the underwriters exercise this option, the underwriters will purchase additional shares from us in approximately the same proportion as shown in the table above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Discounts and Commissions. </I>The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the
underwriters to us per share of common stock, or the public offering price per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant less the amount paid by the underwriters to us per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant,
as the case may be. The underwriting fee is $&#8195;&#8195;&#8195;&#8195; per share of common stock and per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. The following table shows the per share, per
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the underwriters&#8217; option to purchase additional shares of
common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise&nbsp;of&nbsp;Option&nbsp;to</B><br><B>Purchase&nbsp;Additional&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise&nbsp;of&nbsp;Option&nbsp;to</B><br><B>Purchase&nbsp;Additional&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the total expenses of the offering, excluding underwriting discounts and commissions, will be
approximately $&#8195;&#8195;&#8195;&#8195; and are payable by us. We have agreed to reimburse the underwriters for up to $10,000 for their FINRA counsel fee. In accordance with FINRA Rule 5110, this reimbursed fee is deemed underwriting
compensation for this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters propose to offer the shares of common stock and <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to the public at the public offering price set forth on the cover of this prospectus supplement. The underwriters may offer the shares of common stock and
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to securities dealers at the public offering price less a concession not in excess of $&#8195;&#8195;&#8195;&#8195;&#8195; per share and $&#8195;&#8195;&#8195;&#8195;per <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant. If all of the shares and pre-funded warrants are not sold at the public offering price, the underwriters may change the offering price and other selling terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Discretionary Accounts. </I>The underwriters do not intend to confirm sales of the shares of common stock and <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to any accounts over which they have discretionary authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stabilization.
</I>In connection with this offering, the underwriters may engage in stabilizing transactions, overallotment transactions, syndicate covering transactions, penalty bids and purchases to cover positions created by short sales. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stabilizing transactions permit bids to purchase shares of common stock so long as the stabilizing bids do not
exceed a specified maximum and are engaged in for the purpose of preventing or retarding a decline in the market price of the common stock while the offering is in progress. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Overallotment transactions involve sales by the underwriter of shares of common stock in excess of the number of
shares the underwriter is obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriter is
not greater than the number of shares that they may purchase in the option to purchase additional shares. In a naked short position, the number of shares involved is greater than the number of shares in the option to purchase additional shares. The
underwriters may close out any short position by exercising their option to purchase additional shares and/or purchasing shares in the open market. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Syndicate covering transactions involve purchases of common stock in the open market after the distribution has
been completed in order to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as
compared with the price at which they may purchase shares through exercise of the option to purchase additional shares. If the underwriters sell more shares than could be covered by exercise of the option to purchase additional shares and,
therefore, have a naked short position, the position can be closed out only by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward
pressure on the price of the shares in the open market that could adversely affect investors who purchase in the offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Penalty bids permit the underwriters to reclaim a selling concession from a syndicate member when the common
stock originally sold by that syndicate member is purchased in stabilizing or syndicate covering transactions to cover syndicate short positions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market
price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock in the open market may be higher than it would otherwise be in the absence of these transactions.
Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our common stock. These transactions may be effected on the Nasdaq Stock Market, in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise and, if commenced, may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements. </I>Pursuant to certain
<FONT STYLE="white-space:nowrap">&#8216;&#8216;lock-up&#8217;&#8217;</FONT> agreements, we have agreed, subject to certain exceptions, not to offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly or submit to, or file with, the SEC a registration statement under the Securities Act relating
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to, any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock, or publicly disclose the intention to undertake any of the foregoing, or enter
into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common stock or any such other securities, whether any such transaction described above is to be settled by delivery of common
stock or such other securities, in cash or otherwise, without the prior written consent of TD Securities (USA) LLC, other than the securities to be sold pursuant to the underwriting agreement and the delivery of any warrant shares upon any exercise
of the warrants, for a period ending at the close of business 30 days after the date of this prospectus supplement (the &#8220;restricted period&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions described above do not apply to (i) the issuance of shares of common stock or securities convertible into or exercisable for
shares of common stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of warrants or options (including net exercise) or the settlement of RSUs (including net or settlement), in each case outstanding
as of the date of this prospectus supplement and disclosed in this prospectus supplement; (ii) grants of stock options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of shares of common stock or securities convertible
into or exercisable or exchangeable for shares of common stock (whether upon the exercise of stock options or otherwise) to our employees, officers, directors, advisors, or consultants pursuant to the terms of an equity compensation plan in effect
as of the closing date of this offering and described in this prospectus supplement, provided that such recipients enter into a lock-up agreement with the underwriters; (iii) the issuance of up to 5% of the outstanding shares of common stock, or
securities convertible into, exercisable for, or which are otherwise exchangeable for, common stock, immediately following the closing date of this offering, in connection with one or more acquisitions of a company or a business, assets or
technology of another person or entity, joint ventures, commercial relationships or strategic alliances (including but not limited to marketing or distribution arrangements, collaboration agreements or intellectual property license agreements),
provided that such recipients enter into a lock-up agreement with the underwriters; (iv) the filing of any registration statement on Form S-8 relating to securities granted or to be granted pursuant to any equity incentive plan or employee stock
purchase plan in effect on the date of this prospectus supplement and or any assumed benefit plan pursuant to an acquisition or similar strategic transaction; or (v) the filing by us of any registration statement on Form S-3 or a successor form
thereto relating to our &#8220;at-the-market&#8221; offerings pursuant to that certain Sales Agreement between us and TD Securities (USA) LLC, dated January 6, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our executive officers and directors (the &#8220;lock-up parties&#8221;) have agreed they will not, and will not cause any direct
or indirect affiliate to, during the restricted period, (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise
transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock (including without limitation, common stock or such other securities which may be deemed to
be beneficially owned by the lock-up party in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant) (collectively with the common stock, &#8220;Lock-Up Securities&#8221;),
(2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the Lock-Up Securities, whether any such transaction described in clause (1) or (2) above is to
be settled by delivery of Lock-Up Securities, in cash or otherwise, (3) make any demand for or exercise any right with respect to the registration of any Lock-Up Securities, or (4) publicly disclose the intention to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exceptions permit the lock-up parties, among other things and subject to restrictions, to make transfers: (a) (i)&nbsp;as a bona fide gift
or gifts, or for bona fide estate planning purposes, (ii)&nbsp;by will, other testamentary document or intestacy, (iii)&nbsp;to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, or if the
undersigned is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust, (iv)&nbsp;to a partnership, limited liability company or other entity of which the lock-up party and/or its immediate family are the
legal and beneficial owner of all of the outstanding equity securities or similar interests, (v)&nbsp;to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clauses (i)&nbsp;through (iv) above, (vi)&nbsp;if the lock-up party is a corporation, partnership, limited liability company, trust or other business entity, (A)&nbsp;to another corporation,
partnership, limited liability company, trust or other business entity that is an affiliate, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control, or (B)&nbsp;as part of a distribution,
transfers or dispositions without consideration to its stockholders, partners, members, beneficiaries or other equity holders, (vii)&nbsp;by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree,
separation agreement or other court order, (viii)&nbsp;to us (A)&nbsp;from an employee or other service provider of ours upon death, disability or termination of employment or service, in each case, of such employee or service provider or
(B)&nbsp;pursuant to an agreement under which we have a right of first refusal with respect to transfers of such securities, (ix)&nbsp;as part of a sale of these shares acquired in open market transactions after the closing date for this offering,
(x)&nbsp;to us in connection with the vesting, settlement, or exercise of restricted stock units, options, warrants or other rights to purchase shares of common stock (including, in each case, by way of &#8220;net&#8221; or &#8220;cashless&#8221;
exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting, settlement, or exercise of such restricted stock units, options, warrants or rights, provided that any such shares of common stock
received upon such exercise, vesting or settlement shall be subject to the terms of the <FONT STYLE="white-space:nowrap">&#8220;lock-up&#8221;</FONT> agreement, and provided further that any such restricted stock units, options, warrants or rights
are held pursuant to an agreement or equity awards granted under a stock incentive plan or other equity award plan, each such agreement or plan which is described in the Registration Statement, the Pricing Disclosure Package and this prospectus
supplement, or (xi)&nbsp;pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by our Board of Directors and made to all holders of our capital stock involving a Change of Control (for
purposes hereof, &#8220;Change of Control&#8221; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated
persons, of shares of capital stock if, after such transfer, such person or group of affiliated persons would hold more than 50% of our outstanding voting securities (or the surviving entity)); provided that in the event that such tender offer,
merger, consolidation or other similar transaction is not completed, the Lock-up Securities shall remain subject to the provisions of the <FONT STYLE="white-space:nowrap">&#8220;lock-up&#8221;</FONT> agreement; provided that (A) in the case of any
transfer or distribution pursuant to clauses (a)(i), (ii), (iii), (iv), (v), (vi) and (vii), such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the Representative a
lock-up letter, (B) in the case of any transfer or distribution pursuant to clause (a)(i), (iii), (iv), (v), (vi) and (ix), no filing by any party under the Exchange Act, or other public announcement shall be required or shall be made voluntarily in
connection with such transfer or distribution (other than a filing on Schedule 13D, 13F or 13G, a Form 5 made after the expiration of the Restricted Period referred to above or, in the case of (a)(i) only, a filing on Form 4 during the Restricted
Period, each of which shall clearly indicate in the footnotes thereto the nature and conditions of such transfer) and (C) in the case of any transfer or distribution pursuant to clause (a)(ii), (vii), (viii) and (x) it shall be a condition to such
transfer that no public filing, report or announcement shall be voluntarily made and if any filing under Section 16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of
common stock in connection with such transfer or distribution shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer; (b)
exercise outstanding options, settle restricted stock units or other equity awards or exercise warrants pursuant to plans described in the this prospectus supplement, provided that any Lock-up Securities received upon such exercise, vesting or
settlement shall be subject to the terms of the lock-up agreement; (c) convert outstanding preferred stock, warrants to acquire preferred stock or convertible securities into shares of common stock or warrants to acquire shares of common stock;
provided that any such shares of common stock or warrants received upon such conversion shall be subject to the terms of the lock-up; and (d) establish trading plans pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of
Lock-Up Securities; provided that (1) such plans do not provide for the transfer of Lock-Up Securities during the Restricted Period and (2) no filing by any party under the Exchange Act or other public announcement shall be required or made
voluntarily in connection with such trading plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Selling Restrictions </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Canada</I>. The shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants may be sold only to purchasers
purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act
</I>(Ontario), and are permitted clients, as defined </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the common stock must be made
in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this
prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the
purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts </I>(NI <FONT
STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Switzerland. </I>The securities will not be offered, directly or indirectly, to the public in Switzerland and this
prospectus does not constitute a public offering prospectus as that term is understood pursuant to article 652a or 1156 of the Swiss Federal Code of Obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>European Economic Area. </I>In relation to each Member State of the European Economic Area (each, a &#8220;Member State&#8221;), no shares
of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants have been offered or will be offered pursuant to the offering to the public in that Member State prior to the publication of a prospectus in relation to the shares of
common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants which has been approved by the competent authority in that Member State or, where appropriate, approved in another Member State and notified to the competent authority in
that Member State, all in accordance with the Prospectus Regulation, except that shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants may be offered to the public in that Member State at any time: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. to any legal entity which is a qualified investor as defined under Article 2 the Prospectus Regulation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 the Prospectus Regulation), subject
to obtaining the prior consent of the representatives for any such offer; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. in any other circumstances falling within Article 1(4) of
the Prospectus Regulation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants shall
require us or any of the representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to the shares of common stock or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to
purchase or subscribe for any shares, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>United
Kingdom. </I>No shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in
relation to the shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants which has been approved by the Financial Conduct Authority, except that the shares may be offered to the public in the United Kingdom at any time:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. to any legal entity which is a qualified investor as defined under Article 2 of the U.K. Prospectus Regulation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation),
subject to obtaining the prior consent of the representatives for any such offer; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. in any other circumstances falling within Section&nbsp;86 of the FSMA, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of the shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants shall require the Issuer or any
Manager to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the U.K. Prospectus Regulation. For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in
relation to the shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any
shares and the expression &#8220;U.K. Prospectus Regulation&#8221; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#8220;qualified investors&#8221; (as defined in the Prospectus Regulation)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#8220;Order&#8221;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of
the Order (all such persons together being referred to as &#8220;relevant persons&#8221;) or otherwise in circumstances which have not resulted and will not result in an offer to the public of the shares of common stock or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants in the United Kingdom within the meaning of the Financial Services and Markets Act 2000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it
as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Hong Kong. </I>The shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants have not been offered or sold and
will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the &#8220;SFO&#8221;) of Hong
Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong) (the
&#8220;CO&#8221;), or which do not constitute an offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for
the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than
with respect to shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in the SFO
and any rules made thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Singapore. </I>Each underwriter has acknowledged that this prospectus supplement has not been
registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each underwriter has represented and agreed that it has not offered or sold any shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants
or caused the shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares or cause the shares to be made the subject
of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus supplement or any other document or material in connection with the offer or sale, or invitation for
subscription or purchase, of the shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, whether directly or indirectly, to any person in Singapore other than: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or
amended from time to time (the &#8220;SFA&#8221;)) pursuant to Section&nbsp;274 of the SFA; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. to a relevant person (as defined in
Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. otherwise pursuant to, and in accordance with the conditions of, any other applicable
provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold
investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. a
trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities or securities-based derivatives contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#8217;
rights and interest (however described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section&nbsp;275(1A) or
Section&nbsp;276(4)(i)(B) of the SFA; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) where no consideration is or will be given for the transfer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) where the transfer is by operation of law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) as specified in Section&nbsp;276(7) of the SFA; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives
Contracts) Regulations 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Singapore SFA Product Classification &#8212; In connection with Section&nbsp;309B of the SFA and the CMP Regulations 2018,
unless otherwise specified before an offer of shares, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the securities are &#8220;prescribed capital markets products&#8221; (as defined
in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT>
Notice on Recommendations on Investment Products). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Israel. </I>In the State of Israel this prospectus supplement shall not be regarded
as an offer to the public to purchase shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants under the Israeli Securities Law, 5728&nbsp;&#8211;&nbsp;1968, which requires a prospectus to be published and authorized by
the Israel Securities Authority, if it complies with certain provisions of Section&nbsp;15 of the Israeli Securities Law, 5728&#8211;1968, including, inter alia, if: (i)&nbsp;the offer is made, distributed or directed to not more than 35 investors,
subject to certain conditions (the &#8220;Addressed Investors&#8221;); or (ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728&nbsp;&#8211;&nbsp;1968,
subject to certain conditions (the &#8220;Qualified Investors&#8221;). The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed
Investors. The company has not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728&nbsp;&#8211;&nbsp;1968. We have not and will not distribute this prospectus
or make, distribute or direct an offer to subscribe for our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli
Securities Law, 5728&nbsp;&#8211;&nbsp;1968. In particular, we may request, as a condition to be offered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it is an investor falling within one of the categories
listed in the First Addendum to the Israeli Securities Law, 5728&nbsp;&#8211;&nbsp;1968; (ii) which of the categories listed in the First Addendum to the Israeli Securities Law, 5728&nbsp;&#8211;&nbsp;1968 regarding Qualified Investors is applicable
to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728&nbsp;&#8211;&nbsp;1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock; (iv)&nbsp;that the shares
of common stock that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728&nbsp;&#8211;&nbsp;1968: (a) for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a view to resale
within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728&nbsp;&#8211;&nbsp;1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors
may have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#8217;s name, address and passport number or Israeli identification number. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not authorized and do not authorize the making of any offer of securities through any financial intermediary on our behalf, other than
offers made by the underwriters and their affiliates, with a view to the final placement of the securities as contemplated in this document. Accordingly, no purchaser of the shares of common stock or
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, other than the underwriters, is authorized to make any further offer of shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on our behalf or on behalf of
the underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Electronic Offer, Sale and Distribution of Shares. </I>A prospectus in electronic format may be made available on
the websites maintained by the underwriters or selling group members, if any, participating in this offering and the underwriters participating in this offering may distribute prospectuses electronically. The underwriters may agree to allocate a
number of shares to their online brokerage account holders. Internet distributions will be allocated by the underwriters that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format,
the information on these websites is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or any underwriters in its capacity as underwriters, and should not be
relied upon by investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Other Relationships</I>. The underwriters and their affiliates have provided, and may in the future provide,
various investment banking, commercial banking and other financial services for us and our affiliates for which they have received, and may in the future receive, customary fees. TD Securities (USA) LLC is the sales agent under the Sales Agreement.
Under the Sales Agreement, we may offer and sell, from time to time, shares of our common stock through TD Securities (USA) LLC through and &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc846460_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cooley LLP, New York, New York, which has acted as our counsel in connection with this offering, will pass upon the validity of the shares of common stock and
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants offered hereby. Davis Polk&nbsp;&amp; Wardwell LLP, Redwood City, California has acted as counsel to the underwriters in connection with this offering. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc846460_11"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our&nbsp;Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024, as set forth in their reports, which are incorporated by reference in this prospectus supplement and elsewhere in the registration statement of
which this prospectus supplement forms a part. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#8217;s reports, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc846460_12"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus are part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> we filed
with the SEC under the Securities Act and do not contain all of the information set forth in the registration statement and the exhibits thereto. Whenever a reference is made in this prospectus supplement or the accompanying prospectus to any of our
contracts, agreements or other documents, the reference may not be complete, and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference therein. For
further information with respect to us and the securities we are offering under this prospectus supplement, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy
statements and other information regarding issuers that file electronically with the SEC, including us. The address of the SEC website is www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copies of certain information filed by us with the SEC are also available on our website at www.olema.com. Information contained in or accessible through our
website does not constitute a part of this prospectus supplement or the accompanying prospectus and is not incorporated by reference into this prospectus supplement or the accompanying prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc846460_13"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#8220;incorporate by reference&#8221; information from other documents that we file with it, which means that we can disclose important
information to you by referring you to those documents instead of having to repeat the information in this prospectus supplement or the accompanying prospectus. The information incorporated by reference is considered to be part of this prospectus
supplement and the accompanying prospectus, and later information that we file with the SEC (Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39712)</FONT> will automatically update and supersede this information. We incorporate by
reference the documents listed below and any future filings made by us with the SEC (other than Current Reports or portions thereof furnished under Item 2.02 or Item 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such
form that are related to such items and other portions of documents that are furnished, but not filed, pursuant to applicable rules promulgated by the SEC) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the
Exchange Act after the filing and concurrent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effectiveness of the registration statement but prior to the termination of all offerings covered by this prospectus supplement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2024, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1750284/000095017025041204/olma-20241231.htm">March&nbsp;18, 2025</A> (the &#8220;Annual Report&#8221;);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information specifically incorporated by reference into our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;
31, 2024 from our definitive proxy statement on Schedule 14A (other than information furnished rather than filed) filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1750284/000095017025059348/olma-20250428.htm">April&nbsp;28,
 2025</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended
March&nbsp;31, 2025, June&nbsp;30, 2025 and September&nbsp;30, 2025 filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1750284/000095017025070374/olma-20250331.htm">May&nbsp;
13, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1750284/000095017025106565/olma-20250630.htm">August&nbsp;
11, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1750284/000119312525273236/olma-20250930.htm">November&nbsp;10, 2025</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (other than information furnished rather
than filed) filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1750284/000119312525004427/d915597d8k.htm">January&nbsp;
10, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1750284/000095017025086256/olma-20250610.htm">June&nbsp;
13, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1750284/000175028425000007/olma-20250902.htm">September&nbsp;
2, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1750284/000119312525243765/olma-20251018.htm">October&nbsp;20, 2025</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock in our registration statement on Form
<FONT STYLE="white-space:nowrap">8-A</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1750284/000110465920126242/tm2027048-14_8a12b.htm">November&nbsp;17, 2020</A>, including any amendments or reports filed for the
purpose of updating such description, including <A HREF="http://www.sec.gov/Archives/edgar/data/1750284/000155837021003141/tmb-20201231xex4d3.htm">Exhibit 4.3</A> to the Annual Report. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any beneficial owner, to whom a prospectus supplement or the underlying prospectus is delivered, without charge upon
the written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus supplement but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such
documents. You should direct any requests for documents by writing us at 780 Brannan Street, San Francisco, CA 94103, or by telephoning us at (415) <FONT STYLE="white-space:nowrap">651-3316.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or
superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g846460g33y04.jpg" ALT="LOGO" STYLE="width:2.81176in;height:0.855074in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$200,000,000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, Olema
Pharmaceuticals, Inc. may offer and sell up to an aggregate amount of $200,000,000 of any combination of the securities described in this prospectus, either individually or in combination with other securities in one or more offerings. We may also
offer common stock or preferred stock upon conversion of debt securities, common stock upon conversion of preferred stock, or common stock, preferred stock or debt securities upon the exercise of warrants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus provides a general description of the securities we may offer. Each time we offer securities for sale pursuant to this prospectus, we will
provide the specific terms of these offerings and the securities offered in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with such offerings. The
prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing
prospectus, as well as the documents incorporated by reference, before buying any of the securities being offered. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities may be sold directly by
us to investors, through agents designated from time to time or to or through underwriters or dealers, or through a combination of these methods, on a continuous or delayed basis. If any agents, underwriters or dealers are involved in the sale of
any securities with respect to which this prospectus is being delivered, the names of such agents, underwriters or dealers and any applicable fees, commissions, discounts and options to purchase additional shares will be set forth in a prospectus
supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. For additional information, please refer to the sections titled &#8220;About this
Prospectus&#8221; and &#8220;Plan of Distribution&#8221; in this prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No securities may be sold without delivery of this prospectus and the
applicable prospectus supplement describing the method and terms of the offering of such securities. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><I>Investing in our securities involves a high
degree of risk. Before making an investment decision, you should review carefully the risks and uncertainties described under the section titled &#8220;<A HREF="#toca846460_3">Risk Factors</A>&#8221; on page 5 of this prospectus and any similar
section contained in the applicable prospectus supplement and in any free writing prospectuses we may authorize for use in connection with a specific offering, and under similar headings in the documents that are incorporated by reference into this
prospectus. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market under the trading symbol &#8220;OLMA.&#8221; On
January&nbsp;3,&nbsp;2025, the last reported sale price of our common stock was $5.89 per share. The applicable prospectus supplement will contain information, where applicable, as to other listings, if any, on The Nasdaq Global Select Market or
other securities exchange of the securities covered by the applicable prospectus supplement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any
state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is January&nbsp;15, 2025. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_9">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_12">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca846460_13">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca846460_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and Exchange
Commission, or SEC, utilizing a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may offer and sell shares of our common stock and preferred stock, various series of debt securities and/or warrants to purchase up
to an aggregate amount of $200,000,000 of any of such securities, either individually or in combination with other securities, in one or more offerings. This prospectus provides you with a general description of the securities we may offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time we offer securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of
that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may
authorize to be provided to you may also add, update or change any of the information contained in this prospectus or in the documents that we have incorporated by reference into this prospectus. If there is any inconsistency between the information
in this prospectus and any applicable prospectus supplement or free writing prospectus, you should rely on the prospectus supplement or free writing prospectus, as applicable; provided that, if any statement in one of these documents is inconsistent
with a statement in another document having a later date&#8212;for example, a document incorporated by reference in this prospectus or any prospectus supplement&#8212;the statement in the document having the later date modifies or supersedes the
earlier statement. We urge you to read carefully this prospectus, any applicable prospectus supplement and any free writing prospectuses we may authorize for use in connection with a specific offering, together with the information incorporated
herein by reference as described under the sections titled &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference,&#8221; before buying any of the securities being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide you with any information other than that contained or incorporated by reference in this prospectus or in any
prospectus supplement or free writing prospectus prepared by us or on our behalf or to which we have referred you. We have not authorized any other person to provide you with different or additional information. If anyone provides you with different
or inconsistent information, you should not rely on it. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities
offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information appearing in this prospectus, any
applicable prospectus supplement and any related free writing prospectus that we may authorize for use in connection with this offering is accurate only as of the date on the front of the document and any information we have incorporated by
reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any related free writing prospectus, or any sale of a security. Our
business, financial condition, results of operations and prospects may have changed since those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated
by reference herein contain summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the
actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those
documents as described below under the sections titled &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, as used in this prospectus, the terms &#8220;Olema,&#8221; &#8220;Olema Pharmaceuticals,&#8221; &#8220;Company,&#8221;
&#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Olema Pharmaceuticals, Inc. and, where appropriate, its subsidiaries on a consolidated basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca846460_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference in this prospectus and does not contain all
of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our
securities discussed under the section titled &#8220;Risk Factors&#8221; contained herein and in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by
reference into this prospectus and the applicable prospectus supplement. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration
statement of which this prospectus is a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next generation targeted therapies for
women&#8217;s cancers. We are advancing our pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant <FONT
STYLE="white-space:nowrap">(OP-1250),</FONT> is a novel orally-available small molecule with dual activity as both a complete estrogen receptor, or ER, antagonist, or CERAN, and a selective ER degrader, or SERD, currently being investigated in
patients with recurrent, locally advanced or metastatic <FONT STYLE="white-space:nowrap">ER-positive,</FONT> or ER+, human epidermal growth factor receptor <FONT STYLE="white-space:nowrap">2-negative,</FONT> or HER2-, breast cancer. In preclinical
models, palazestrant binds and completely blocks <FONT STYLE="white-space:nowrap">ER-driven</FONT> transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer including activity in central nervous system, or CNS,
metastases models. In clinical studies across more than 400 patients, palazestrant has demonstrated strong anti-tumor activity, attractive pharmacokinetics and prolonged drug exposure, favorable tolerability, and combinability with CDK4/6 inhibitors
with no significant drug-drug interaction. Palazestrant is being evaluated as a single agent in an ongoing Phase 3 clinical trial, <FONT STYLE="white-space:nowrap">OPERA-01,</FONT> and in Phase 1/2 combination studies with a CDK4/6 inhibitor
(palbociclib or ribociclib), a phosphatidylinositol 3 kinase alpha, or PI3Ka, inhibitor (alpelisib), and a Phase 1b/2 combination study with an mTOR inhibitor (everolimus). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factor Summary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in our securities involves
a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and uncertainties described under the section titled &#8220;Risk Factors&#8221; contained herein and in the applicable prospectus
supplement and any related free writing prospectus, and discussed under the sections titled &#8220;Risk Factors,&#8221; &#8220;Risk Factor Summary&#8221; or similar titles contained in our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and other filings we make with the SEC, which are incorporated by reference into this prospectus in their entirety, together with other
information in this prospectus, the documents incorporated by reference and any free writing prospectus that we may authorize for use in connection with a specific offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were initially incorporated in
Delaware in August 2006 under the name CombiThera, Inc., and we commenced operations in March 2007. In March 2009, we changed our name to Olema Pharmaceuticals, Inc. Our principal executive offices are located at 780 Brannan Street, San Francisco,
California 94103, and our telephone number is (415) <FONT STYLE="white-space:nowrap">651-3316.</FONT> Our website address is www.olema.com. Information contained in, or accessible through, our website is not a part of this prospectus, and the
inclusion of our website address in this prospectus is only an inactive textual reference. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We use the Olema Oncology logo and other marks as trademarks in the United States and other countries. This
prospectus contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may
appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or TM symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of
the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other
entity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. Smaller reporting companies may take advantage of certain scaled disclosures,
including, among other things, providing only two years of audited financial statements in their Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> not being required to comply with the auditor attestation requirements of
Section&nbsp;404 of the Sarbanes-Oxley Act and having reduced disclosure obligations regarding executive compensation. We will be able to take advantage of these reduced disclosures for so long as our voting and
<FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is
less than $100.0&nbsp;million during the most recently completed fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer shares of our common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either
individually or in combination with other securities, up to an aggregate offering amount of $200,000,000, from time to time in one or more offerings under this prospectus, together with the applicable prospectus supplement and any related free
writing prospectus, at prices and on terms to be determined by market conditions at the time of any offering. We may also offer common stock, preferred stock and/or debt securities upon the exercise of warrants. This prospectus provides you with a
general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the
securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">designation or classification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">aggregate principal amount or aggregate offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maturity date, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">original issue discount, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rates and times of payment of interest or dividends, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redemption, conversion, exercise, exchange or sinking fund terms, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ranking; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictive covenants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting or other rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments
in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">material or special U.S. federal income tax considerations, if any. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement and any related free writing prospectus that we may authorize to be
provided to you may also add, update or change any of the information contained in this prospectus or in the documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not
registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the securities directly to
investors or to or through agents, underwriters or dealers. We, and our agents or underwriters, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities to or through agents or underwriters,
we will include in the applicable prospectus supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names of those agents or underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applicable fees, discounts and commissions to be paid to them; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">details regarding over-allotment or other options, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the net proceeds to us, if any. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Common Stock</I>. We may issue shares of our common stock from time to time. The holders of common stock are entitled to one vote per share on all matters
to be voted on by the stockholders. Subject to the preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably any dividends our board of directors declares out of
funds legally available for the payment of dividends. If we are liquidated, dissolved or wound up, the holders of common stock are entitled to share pro rata in all assets remaining after payment of liabilities and liquidation preferences of any
outstanding shares of preferred stock. Holders of common stock have no preemptive rights or rights to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock. In this
prospectus, we have summarized certain general features of the common stock under the section titled &#8220;Description of Capital Stock&#8212;Common Stock.&#8221; We urge you, however, to read the applicable prospectus supplement (and any related
free writing prospectus that we may authorize to be provided to you) related to any common stock being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preferred Stock.</I> We may issue
shares of our preferred stock from time to time, in one or more series. Our board of directors will determine the designations, voting powers, preferences and rights of the preferred stock, as well as the qualifications, limitations or restrictions
thereof, including dividend rights, conversion rights, preemptive rights, terms of redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of any series. Convertible
preferred stock will be convertible into our common stock or exchangeable for other securities. Conversion may be mandatory or at your option and would be at prescribed conversion rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we sell any series of preferred stock under this prospectus as supplemented by a prospectus supplement and, if applicable, a free writing prospectus, we
will fix the designations, voting powers, preferences and rights of the preferred stock of each such series, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file
as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that contains the terms of the series of preferred
stock we are offering. In this prospectus, we have summarized certain general features of the preferred stock under the section titled &#8220;Description of Capital Stock&#8212;Preferred Stock.&#8221; We urge you, however, to read the applicable
prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the
applicable series of preferred stock. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Debt Securities. </I>We may issue debt securities from time to time, in one or more series, as either
senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in right of
payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible or exchangeable debt securities will be convertible into or exchangeable for our common stock or our other
securities. Conversion or exchange may be mandatory or optional (at our option or the holders&#8217; option) and would be at prescribed conversion or exchange prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The debt securities will be issued under an indenture that we will enter into with a national banking association or other eligible party, as trustee. In this
prospectus, we have summarized certain general features of such debt securities under the section titled &#8220;Description of Debt Securities.&#8221; We urge you, however, to read the applicable prospectus supplement (and any related free writing
prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indenture and any supplemental indentures that contain the terms of the debt securities. We have filed the form
of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the
registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Warrants.</I>
We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or in combination with common stock, preferred stock and/or debt securities offered by any
prospectus supplement. In this prospectus, we have summarized certain general features of the warrants under the section titled &#8220;Description of Warrants.&#8221; We urge you, however, to read the applicable prospectus supplement (and any
related free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as the form of warrant and/or the warrant agreement and warrant certificate, as applicable, that contain
the terms of the warrants. We have filed the forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that we may offer as exhibits to the registration statement of which this prospectus is a part. We
will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant and/or the warrant agreement and warrant certificate, as applicable,
that contain the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrants may be issued under a warrant agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if any,
in the applicable prospectus supplement relating to a particular series of warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds from the sale of the securities offered by us hereunder, if any, for working capital and general corporate
purposes, including research and development expenses, general and administrative expenses, and capital expenditures, or for any other purpose we describe in any applicable prospectus supplement or any free writing prospectus we may authorize for
use in connection with a specific offering. See the section titled &#8220;Use of Proceeds&#8221; in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market
Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#8220;OLMA.&#8221; The applicable prospectus supplement will
contain information, where applicable, as to other listings, if any, on The Nasdaq Global Select Market or any other securities market or other exchange of the securities covered by the applicable prospectus supplement. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca846460_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and
uncertainties described under the section titled &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, as well as the risk factors described in our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and any Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and any amendments thereto reflected in subsequent filings
with the SEC, which are incorporated by reference into this prospectus in their entirety, together with other information in this prospectus, the documents incorporated by reference and any free writing prospectus that we may authorize for use in
connection with a specific offering. The risks described in these documents are not the only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive, regulatory or other
factors that could have material adverse effects on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If
any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our securities to decline, resulting in a loss of all or part of your
investment. Please also carefully read the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca846460_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and any accompanying prospectus supplement, as well as the documents incorporated by reference in this prospectus or any accompanying
prospectus supplement, contain &#8220;forward-looking statements&#8221; within the meaning of Section&nbsp;27A of the Securities Act, Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the Private
Securities Litigation Reform Act of 1995. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. These statements relate to
future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results,
performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sufficiency of our existing cash to fund our future operating expenses and capital expenditure requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional
financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of developing palazestrant
<FONT STYLE="white-space:nowrap">(OP-1250),</FONT> <FONT STYLE="white-space:nowrap">OP-3136</FONT> or any other product candidates we may develop, and conducting nonclinical studies and clinical trials, including our palazestrant Phase 1/2 clinical
studies and Phase 3 clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and costs involved in obtaining and maintaining regulatory approval of palazestrant, <FONT
STYLE="white-space:nowrap">OP-3136</FONT> or any other product candidates we may develop, and the timing or likelihood of regulatory filings and approvals, including our expectation to seek special designations for our product candidates for various
diseases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans relating to commercializing palazestrant, <FONT STYLE="white-space:nowrap">OP-3136</FONT> and any other
product candidates we may develop, if approved, including the geographic areas of focus and our ability to grow a sales team; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our strategic plans for our business and palazestrant,
<FONT STYLE="white-space:nowrap">OP-3136</FONT> or any other product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the market opportunity for palazestrant, <FONT STYLE="white-space:nowrap">OP-3136</FONT> or any other
product candidates we may develop in each of the diseases we target; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct nonclinical research activities, and for the manufacture of
palazestrant, <FONT STYLE="white-space:nowrap">OP-3136</FONT> and any other product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the beneficial characteristics, safety, efficacy and therapeutic effects of palazestrant, <FONT
STYLE="white-space:nowrap">OP-3136</FONT> and any other product candidates we may develop, in each case, as a monotherapy and in combination with other drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of our total addressable market size, including the number of patients in the United States who
suffer from the diseases we target and the number of subjects that will enroll in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress and focus of our current and future clinical trials, and the reporting of data from those trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance product candidates into and successfully complete clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our clinical trials to demonstrate the safety and efficacy of palazestrant, <FONT
STYLE="white-space:nowrap">OP-3136</FONT> and any other product candidates we may develop, and other positive results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry, including competing product candidates and therapies;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans relating to the further development and manufacturing of palazestrant,
<FONT STYLE="white-space:nowrap">OP-3136</FONT> and any other product candidates we may develop, including additional indications that we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">existing regulations and regulatory developments in the United States and other jurisdictions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our potential and ability to successfully manufacture and supply palazestrant,
<FONT STYLE="white-space:nowrap">OP-3136</FONT> and any other product candidates we may develop for clinical trials and for commercial use, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of palazestrant, <FONT STYLE="white-space:nowrap">OP-3136</FONT> and any
other product candidates we may develop, as well as the pricing and reimbursement of palazestrant, <FONT STYLE="white-space:nowrap">OP-3136</FONT> and any other product candidates we may develop, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our continued reliance on third parties to conduct additional clinical trials of palazestrant, <FONT
STYLE="white-space:nowrap">OP-3136</FONT> and any other product candidates we may develop, and for the manufacture of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans and ability to obtain and protect intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights, including
palazestrant, <FONT STYLE="white-space:nowrap">OP-3136</FONT> and any other product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to access capital resources on favorable terms, or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to retain the continued service of our key personnel and to identify, hire, and then retain
additional qualified personnel; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intended use of the net proceeds from offerings of our securities under this prospectus.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All statements other than statements of historical facts contained in this prospectus and the documents incorporated by reference
herein are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking statements. This prospectus and the documents incorporated by reference herein also contain estimates and other statistical data made by independent parties and by us relating
to market size and growth and other data about our industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This data involves a number of assumptions and limitations, and you are cautioned not to
give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#8220;anticipates,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221;
&#8220;expects,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;will&#8221; or the negative of these terms or other similar
expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. Given these risks and uncertainties, you
should not place undue reliance on these forward-looking statements. We discuss in greater detail, and incorporate by reference into this prospectus in their entirety, many of these risks and uncertainties under the section titled &#8220;Risk
Factors&#8221; contained in the applicable prospectus supplement, in any free writing prospectus we may authorize for use in connection with a specific offering, and in our most recent Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> and Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as any amendments thereto reflected in subsequent filings with the SEC. Also, these forward-looking statements represent
our estimates and assumptions only as of the date of the document containing the applicable statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events
or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should read this prospectus, the applicable prospectus supplement,
together with the documents we have filed with the SEC that are incorporated by reference herein and therein, and any free writing prospectus we have authorized for use in connection with a specific offering completely and with the understanding
that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and
opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or
incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not
to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca846460_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will retain broad discretion over the use of the net proceeds from the sale of securities offered by us hereby. We currently intend to use the net proceeds
from the sale of the securities offered by us hereunder, if any, for working capital and general corporate purposes, including research and development expenses, general and administrative expenses and capital expenditures, or for any other purpose
we describe in any applicable prospectus supplement or any free writing prospectus we may authorize for use in connection with a specific offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
amounts and timing of our use of the net proceeds from this offering will depend on a number of factors, such as the timing and progress of our research and development efforts, the timing and progress of any partnering and commercialization
efforts, technological advances and the competitive environment for our products. As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to us from the sale of the securities offered by us
hereunder. Accordingly, our management will have broad discretion in the timing and application of these proceeds. Pending application of the net proceeds as described above, we intend to invest the net proceeds in a variety of capital preservation
investments, including short-term, investment-grade, and interest-bearing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca846460_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, our authorized capital stock consists of 490,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000
shares of preferred stock, par value $0.0001 per share. A description of material terms and provisions of our amended and restated certificate of incorporation and amended and restated bylaws affecting the rights of holders of our capital stock is
set forth below. The description is intended as a summary and is qualified in its entirety by reference to our amended and restated certificate of incorporation and our amended and restated bylaws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The common stock is entitled to one vote per share on any matter that is submitted to a vote of our stockholders. Our amended and restated certificate of
incorporation does not provide for cumulative voting for the election of directors. Our amended and restated certificate of incorporation establishes a classified board of directors that is divided into three classes with staggered three-year terms.
Only the directors in one class are subject to election by a plurality of the votes cast at each annual meeting of our stockholders, with the directors in the other classes continuing for the remainder of their respective three-year terms. The
affirmative vote of holders of at least 66&nbsp;2/3% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, is required to amend certain provisions of our amended and restated certificate of
incorporation, including provisions relating to amending our amended and restated bylaws, the classified structure of our board of directors, the size of our board of directors, removal of directors, director liability, vacancies on our board of
directors, special meetings, stockholder notices, actions by written consent and exclusive jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Economic rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise expressly provided in our amended and restated certificate of incorporation or required by applicable law, all shares of common stock will
have the same rights and privileges and rank equally, share ratably, and be identical in all respects for all matters, including those described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends</I>. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock are entitled
to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation rights</I>. On our liquidation, dissolution, or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the holders of common stock will be
entitled to share equally, identically, and ratably in all assets remaining after the payment of any liabilities, liquidation preferences and accrued or declared but unpaid dividends, if any, with respect to any outstanding preferred stock, unless a
different treatment is approved by the affirmative vote of the holders of a majority of the outstanding shares of such affected class, voting separately as a class. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No preemptive or similar rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of
our shares of common stock are not entitled to preemptive rights, and are not subject to conversion, redemption or sinking fund provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred
Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one
or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions
thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that
could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other
things, have the effect of delaying, deferring or preventing a change in our control that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting and other rights of the holders
of common stock. We have no current plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will fix the designations, voting powers, preferences and rights of
the preferred stock of each series we issue under this prospectus, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration
statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that contains the terms of the series of preferred stock we are offering. We will
describe in the applicable prospectus supplement the terms of the series of preferred stock being offered, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and stated value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares we are offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the liquidation preference per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate, period and payment date and method of calculation for dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends will be cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if
cumulative, the date from which dividends will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those
redemption and repurchase rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange or market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price,
or how it will be calculated, and the conversion period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or
how it will be calculated, and the exchange period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preemptive rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on transfer, sale or other assignment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interests in the preferred stock will be represented by depositary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of material United States federal income tax considerations applicable to the preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate,
dissolve or wind up our affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limitations on the issuance of any class or series of preferred stock ranking senior to or on a parity with
the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-takeover provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws, which are summarized below, may have
the effect of delaying, deferring or discouraging another person from acquiring control of our company. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe
that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an
improvement of their terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certificate of incorporation and bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because our stockholders do not have cumulative voting rights, stockholders holding a majority of the voting power of our shares of common stock are able to
elect all of our directors. Our amended and restated certificate of incorporation and our amended and restated bylaws provide for stockholder actions at a duly called meeting of stockholders. A special meeting of stockholders may be called by a
majority of our board of directors, the chair of our board of directors, or our chief executive officer or president. Our amended and restated bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual
meeting of our stockholders, including proposed nominations of persons for election to our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors is divided into
three classes with staggered three-year terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing provisions make it more difficult for another party to obtain control of us by replacing our
board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the
authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy
fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in our control or management. As a consequence, these
provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the Delaware general corporation law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, or DGCL, which prohibits a Delaware corporation from engaging in any business
combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, subject to certain exceptions. In general, Section&nbsp;203 defines an &#8220;interested
stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the
outstanding voting stock of the corporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Choice of forum </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of
the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any
appellate court therefrom is the sole and exclusive forum for the following claims or causes of action under the Delaware statutory or common law: (i)&nbsp;any derivative claim or cause of action brought on our behalf; (ii)&nbsp;any claim or cause
of action for a breach of fiduciary duty owed by any of our current or former directors, officers, or other employees to us or our stockholders; (iii)&nbsp;any claim or cause of action against us or any of our current or former directors, officers
or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other employees arising out of or pursuant to any provision of the DGCL, our amended and restated certificate of incorporation, or our bylaws (as each may be amended from time to time); (iv) any
claim or cause of action seeking to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws (as each may be amended from time to time, including any right,
obligation, or remedy thereunder); (v) any claim or cause of action as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi)&nbsp;any claim or cause of action against us or any of our current or former
directors, officers, or other employees governed by the internal-affairs doctrine or otherwise related to our internal affairs, in all cases to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over
the indispensable parties named as defendants. This choice of forum provision would not apply to claims or causes of action brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the
federal courts have exclusive jurisdiction. Our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America are the exclusive forum for resolving any complaint asserting a cause
of action arising under the Securities Act. Additionally, our amended and restated certificate of incorporation provides that any person or entity holding, owning or otherwise acquiring any interest in any of our securities shall be deemed to have
notice of and consented to these provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing on The Nasdaq Global Select Market </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common
stock is listed on The Nasdaq Global Select Market under the symbol &#8220;OLMA.&#8221; The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on The Nasdaq Global Select Market or any
securities market or other exchange of the preferred stock covered by such prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca846460_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt.
While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus
supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below, and the applicable prospectus supplement, to the extent inconsistent with any portion of the description of our debt
securities contained in this prospectus, will supersede the applicable portion of the description contained in this prospectus. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to any supplemental
indentures that specify the terms of a particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will issue the debt securities under the indenture that we will enter
into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an exhibit to the registration statement of which
this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be
incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary of material provisions of the debt securities and the indenture
is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing
prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture does not limit the amount of debt
securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and
sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against changes in our operations,
financial condition or transactions involving us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue the debt securities issued under the indenture as &#8220;discount securities,&#8221; which
means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#8220;original issue discount,&#8221; or OID, for U.S. federal
income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in the
applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit upon the aggregate principal amount that may be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date or dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the form of the debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicability of any guarantees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination
thereof, and the terms of any subordination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities
will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt
securities that is convertible into another security or the method by which any such portion shall be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date
interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at
which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory
sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#8217;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and
any integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series
and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or
securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the
terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the
holders&#8217; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the
series which shall be payable upon declaration of acceleration of the maturity thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the covenants applicable to the particular debt securities being issued, including,
among others, the consolidation, merger or sale covenant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the events of default with respect to the securities and any change in the right of
the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to satisfaction and discharge of the indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to the modification of the indenture both with and without the
consent of holders of debt securities issued under the indenture; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the
equivalent amount in U.S. dollars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interest will be payable in cash or additional debt securities at our or the holders&#8217; option and
the terms and conditions upon which the election may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if
any, and principal amounts of the debt securities of the series to any holder that is not a &#8220;United States person&#8221; for federal tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on transfer, sale or assignment of the debt securities of the series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any
other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will set forth in the
applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether
conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive
would be subject to adjustment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that
restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of ours) must
assume all of our obligations under the indenture or the debt securities, as appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default under the Indenture </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the
indenture with respect to any series of debt securities that we may issue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become
due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in
the payment of interest for this purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same
shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the
maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the
indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice
of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if specified events of bankruptcy, insolvency or reorganization occur. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series occurs and is continuing, other than an
event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given
by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and
accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect
to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the
default or event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee
will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable
indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising
any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it
in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of the debt securities of
any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder has given written notice to the trustee of a continuing event of default with respect to that series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have
made written request, such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee does not institute the proceeding and does not receive from the holders of a majority in aggregate
principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest
on, the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indenture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and the trustee may
change an indenture without the consent of any holders with respect to specific matters: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the provisions described above under the section titled &#8220;Description of Debt
Securities&#8212;Consolidation, Merger or Sale;&#8221; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or
provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of
default or to surrender any right or power conferred upon us in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms,
or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the interests of any holder of debt securities of any series in
any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any
series as provided above under the section titled &#8220;Description of Debt Securities&#8212;General&#8221; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt
securities, or to add to the rights of the holders of any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust
Indenture Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the
trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to
a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extending the fixed maturity of any debt securities of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any
premium payable upon the redemption of any series of any debt securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment,
supplement, modification or waiver. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified
obligations, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for payment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer or exchange of debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">replace stolen, lost or mutilated debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay principal of and premium and interest on any debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain paying agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hold monies for payment in trust; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recover excess money held by the trustee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensate and indemnify the trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoint any successor trustee. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged, we must deposit with the trustee money or government
obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will issue the debt
securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue
debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in the applicable
prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the
applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the
debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security
registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer
or exchange, but we may require payment of any taxes or other governmental charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will name in the applicable prospectus supplement the security
registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a
change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we elect to redeem the debt securities of any series, we will not be required to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the
opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except
the unredeemed portion of any debt securities we are redeeming in part. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are
specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this
provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities
that it might incur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date
to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us,
except that, unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable
prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents
that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed
at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture and the debt securities, and
any claim, controversy or dispute arising under or related to the indenture or the debt securities, will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act is
applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca846460_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplement and any applicable free writing
prospectus that we may authorize for use in connection with an offering, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or
debt securities and may be issued in one or more series. Warrants may be offered independently or in combination with common stock, preferred stock or debt securities offered by any prospectus supplement. While the terms we have summarized below
will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement and any applicable free writing prospectus that we
may authorize for use in connection with an offering. The following description of warrants will apply to the warrants offered by this prospectus unless we provide otherwise in the applicable prospectus supplement. The applicable prospectus
supplement for a particular series of warrants may specify different or additional terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed forms of the warrant agreements and forms of
warrant certificates containing the terms of the warrants that may be offered as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or
will incorporate by reference from reports that we file with the SEC, the form of warrant and/or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular series of warrants we are offering, and any
supplemental agreements, before the issuance of such warrants. The following summaries of material terms and provisions of the warrants are subject to, and qualified in their entirety by reference to, all the provisions of the form of warrant and/or
the warrant agreement and warrant certificate, as applicable, and any supplemental agreements applicable to a particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplement related to
the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectus that we may authorize for use in connection with an offering, and the complete form of warrant and/or the warrant agreement and
warrant certificate, as applicable, and any supplemental agreements, that contain the terms of the warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of the series of warrants being offered, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of such securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price and aggregate number of warrants offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency for which the warrants may be purchased; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date on and after which the warrants and the related securities will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of such warrants which may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon
exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or
preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and
the warrants; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise
of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the warrant agreements and warrants may be modified; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of material or special U.S. federal income tax considerations, if any, of holding or exercising the
warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities issuable upon exercise of the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon
such exercise, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium,
if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or
payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe
in the applicable prospectus supplement. The warrants may be exercised as set forth in the prospectus supplement relating to the warrants offered. Unless we otherwise specify in the applicable prospectus supplement, warrants may be exercised at any
time up to the close of business on the expiration date set forth in the prospectus supplement relating to the warrants offered thereby. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon receipt of payment and the warrant or warrant certificate, as applicable, properly completed and duly executed at the corporate trust office of the
warrant agent, if any, or any other office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and deliver the securities purchasable upon such exercise. If less than all of the warrants (or the warrants
represented by such warrant certificate) are exercised, a new warrant or a new warrant certificate, as applicable, will be issued for the remaining warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we otherwise specify in the
applicable prospectus supplement, the warrants and any warrant agreements and any claim, controversy or dispute arising under or related to the warrants or warrant agreements, will be governed by and construed in accordance with the laws of the
State of New York. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each warrant agent, if any, will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or
trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant
agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other
warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca846460_9"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to
those persons who have securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this purpose as the &#8220;holders&#8221; of those securities. These persons are the legal
holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#8220;indirect holders&#8221; of those securities. As we discuss below,
indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry
Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be
represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#8217;s book-entry system. These participating
institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized as the holder of that security. Securities issued in global form will be registered in
the name of the depositary or its participants. Consequently, for securities issued in global form, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The
depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another
or with their customers; they are not obligated to do so under the terms of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, investors in a book-entry security will not own
securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#8217;s book-entry system or holds an interest through a participant. As
long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may terminate a global security or issue securities in <FONT STYLE="white-space:nowrap">non-global</FONT> form. In these cases, investors may
choose to hold their securities in their own names or in &#8220;street name.&#8221; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the
investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For securities held in
street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any applicable
trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or
because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our obligations, as well as the
obligations of any applicable trustee and of any third parties employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name
or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a notice to the legal holder, we have no further responsibility
for the payment or notice even if that legal holder is required, under agreements with depositary participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the
legal holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of the indenture or for other purposes. In such an event, we would seek approval only from the legal
holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Indirect Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold
securities through a bank, broker or other financial institution, either in book-entry form or in street name, you should check with your own institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the performance of third-party service providers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it handles securities payments and notices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would handle a request for the holders&#8217; consent, if ever required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if
that is permitted in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would exercise rights under the securities if there were a default or other event triggering the need for
holders to act to protect their interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are in book-entry form, how the depositary&#8217;s rules and procedures will affect these
matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each security issued in book-entry form will be represented by a global security that we deposit with and register in the name of a financial institution or
its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, DTC will be the depositary for all securities issued in book-entry
form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary,
unless special termination situations arise. We describe those situations below under the section titled &#8220;Special Situations When a Global Security Will Be Terminated&#8221; in this prospectus. As a result of these arrangements, the
depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be
held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a
legal holder of the security, but only an indirect holder of a beneficial interest in the global security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the prospectus supplement for a particular
security indicates that the security will be issued in global form only, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities
through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rights of an indirect holder relating to a global security will be governed by the account rules of the investor&#8217;s financial institution and of the
depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If securities are issued only in the form of a global security, an investor should be aware of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor cannot cause the securities to be registered in his or her name, and cannot obtain <FONT
STYLE="white-space:nowrap">non-global</FONT> certificates for his or her interest in the securities, except in the special situations we describe below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the
securities and protection of his or her legal rights relating to the securities, as we describe above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to sell interests in the securities to some insurance companies and to other
institutions that are required by law to own their securities in <FONT STYLE="white-space:nowrap">non-book-entry</FONT> form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to pledge his or her interest in a global security in circumstances where
certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary&#8217;s policies, which may change from time to time, will govern payments, transfers, exchanges
and other matters relating to an investor&#8217;s interest in a global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we and any applicable trustee have no responsibility for any aspect of the depositary&#8217;s actions or for its
records of ownership interests in a global security, nor do we or any applicable trustee supervise the depositary in any way; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in a
global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions that participate in the depositary&#8217;s book-entry system, and through which an
investor holds its interest in a global security, may also have their own policies affecting payments, notices and other matters relating to the securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any
of those intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When a Global Security Will Be Terminated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a few special situations described below, the global security will terminate and interests in it will be exchanged for physical certificates representing
those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks, brokers or other financial institutions to find out how to have their
interests in securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations occur: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for
that global security and we do not appoint another institution to act as depositary within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we notify any applicable trustee that we wish to terminate that global security; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default has occurred with regard to securities represented by that global security and has not
been cured or waived. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may also list additional situations for terminating a global security
that would apply only to the particular series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of the
institutions that will be the initial direct holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca846460_10a"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, direct sales to the public, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#8220;at-the-market&#8221;</FONT></FONT> offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities to or through one or more underwriters or dealers (acting as
principal or agent), through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the
offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of the underwriters, dealers or agents, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities or other consideration therefor, and the proceeds, if any, we will receive
from the sale; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any over-allotment or other options under which underwriters may purchase additional securities from us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or reallowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange or market on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement. Dealers and agents
participating in the distribution of the securities may be deemed to be underwriters, and compensation received by them on resale of the securities may be deemed to be underwriting discounts. If such dealers or agents were deemed to be underwriters,
they may be subject to statutory liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, they will acquire the securities for their
own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be
subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain
conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any option to purchase additional shares or other option. If a dealer is used in the sale of
securities, we or an underwriter will sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. To the extent required, we will
set forth in the prospectus supplement the name of the dealer and the terms of the transaction. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may use underwriters, dealers or agents with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter,
dealer or agent, the nature of any such relationship. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell securities directly or through agents we designate from time to time. We will name any agent
involved in the offering and sale of securities and we will describe any commissions payable to the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, the agent will act on a best-efforts basis for the period of
its appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may provide agents, underwriters and dealers with indemnification against civil liabilities, including liabilities under the
Securities Act, or contribution with respect to payments that the agents, underwriters or dealers may make with respect to these liabilities. Agents, underwriters and dealers, or their affiliates, may engage in transactions with, or perform services
for, us in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All securities we may offer, other than common stock, will be new issues of securities with no established
trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any underwriter may be granted an option to purchase additional shares and engage in stabilizing transactions, short-covering transactions and penalty
bids in accordance with Regulation M under the Exchange Act. An underwriter&#8217;s option to purchase additional shares involves sales in excess of the offering size, which creates a short position. Stabilizing transactions permit bids to purchase
the underlying security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions involve purchases of the securities, either through exercise of the option to purchase
additional shares or in the open market after the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased
in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any underwriters, dealers or agents that are qualified market makers on The Nasdaq Global Select Market may engage in passive market making transactions in
the common stock on The Nasdaq Global Select Market in accordance with Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the common stock. Passive market
makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if
all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the
securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In compliance with
guidelines of the Financial Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received by any FINRA member or independent broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant
to this prospectus and the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca846460_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, Cooley LLP will pass upon the validity of the securities offered by this prospectus, and
any supplement thereto. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca846460_11"></A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
consolidated financial statements of Olema Pharmaceuticals, Inc. appearing in Olema Pharmaceuticals, Inc.&#8217;s Annual Report (Form <FONT STYLE="white-space:nowrap">10-K)</FONT> for the year ended December&nbsp;31, 2023, have been audited by
Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon included therein, and incorporated herein by reference. Such financial statements are, and audited financial statements to be included in
subsequently filed documents will be, incorporated herein in reliance upon the report of Ernst&nbsp;&amp; Young LLP pertaining to such financial statements (to the extent covered by consents filed with the Securities and Exchange Commission) given
on the authority of such firm as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca846460_12"></A>WHERE YOU CAN FIND MORE INFORMATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of the registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> we filed with the SEC under the Securities
Act and does not contain all the information set forth or incorporated by reference in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be
complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other document.
Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the
Internet at the SEC&#8217;s website at www.sec.gov and can also be accessed free of charge on the Investor section of our website, which is located at ir.olema.com. These filings will be available as soon as reasonably practicable after we
electronically file such material with, or furnish it to, the SEC. The information contained in, or that can be accessed through, our website is not incorporated by reference into this prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca846460_13"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#8220;incorporate by reference&#8221; information from other documents that we file with it, which means that we can disclose important
information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC
prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate by reference into this prospectus the documents listed below and any future filings made by us with the SEC (other than Current Reports or
portions thereof furnished under Item 2.02 or Item 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items and other portions of documents that are furnished, but not filed, pursuant to
applicable rules promulgated by the SEC) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the registration statement of which this
prospectus is a part but prior to the effectiveness of such registration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statement, until we file a post-effective amendment that indicates the termination of all offerings of securities covered by this prospectus: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2023, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001750284/000095017024029281/olma-20231231.htm">March<U></U>&nbsp;11, 2024,</A> or the 2023 Annual Report;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information specifically incorporated by reference into our 2023 Annual Report from our definitive proxy
statement on Schedule 14A, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1750284/000095017024049287/olma-def_14a-2024_proxy.htm">April<U></U>&nbsp;26, 2024</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31,
2024, June&nbsp;30, 2024 and September&nbsp;30, 2024, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001750284/000095017024055686/olma-20240331.htm">May<U></U>&nbsp;
8, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001750284/000095017024091836/olma-20240630.htm">August<U></U>&nbsp;
6, 2024</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001750284/000095017024125427/olma-20240930.htm">November<U></U>&nbsp;12, 2024</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our current reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (other than information furnished rather
than filed), filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001750284/000095017024002543/olma-20240105.htm">January<U></U>&nbsp;
5, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001750284/000095017024002721/olma-20240108.htm">January<U></U>&nbsp;
8, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001750284/000095017024060031/olma-20240515.htm">May<U></U>&nbsp;
15, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001750284/000095017024073749/olma-20240613.htm">June<U></U>&nbsp;
14, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001750284/000095017024080546/olma-20240628.htm">July<U></U>&nbsp;
2, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001750284/000095017024109753/olma-20240927.htm">September<U></U>&nbsp;
27, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001750284/000095017024131965/olma-20241129.htm">December<U></U>&nbsp;
2, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001750284/000095017024134759/olma-20241209.htm">December<U></U>&nbsp;10, 2024</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock in our registration statement on Form
<FONT STYLE="white-space:nowrap">8-A</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1750284/000110465920126242/tm2027048-14_8a12b.htm">November<U></U>&nbsp;17, 2020,</A> including any amendments or reports filed for the
purpose of updating such description, including <A HREF="http://www.sec.gov/Archives/edgar/data/1750284/000155837021003141/tmb-20201231xex4d3.htm">Exhibit 4.3</A> to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year
ended December&nbsp;31, 2020, filed with the SEC on March&nbsp;17, 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any beneficial
owner, to whom a prospectus is delivered, upon written or oral request, without charge to the requester, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including
exhibits which are specifically incorporated by reference into such documents. You should direct any requests for documents by writing us at 780 Brannan Street, San Francisco, California 94103, Attn: Secretary, or by telephoning us at (415) <FONT
STYLE="white-space:nowrap">651-3316.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into
this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this
document modifies or supersedes the statement. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to Purchase Shares of Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g846460g57c33.jpg" ALT="LOGO" STYLE="width:3.32138in;height:0.940819in;">
 </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>TD Cowen </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;&#8195;, 2025 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g846460g33y04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g846460g33y04.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M!@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7%!@8%Q06%AH=)1\:&R,<%A8@
M+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'"@@*$PH*$R@:%AHH*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*/_
M !$( 0$#3 ,!(@ "$0$#$0'_Q  <  $  @,! 0$             !@<$!0@"
M P'_Q !3$  ! P("!08&# P% P0#   !  (#! 4&$0<2(3%!$U%A<8&1(C:A
ML;+1%!4C,C5"4E1B<G3!%A<S0U5S@I*3L\+2)%.BH^$E-/ FE.+Q1&-D_\0
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M1.)HX/<H!SCB[M/DR4\TM8J%)2NLM#)_B9F_XAS3[QA^+UGS=:IQ6(+] )(
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M ''>M;=$&H_!RU?-?]QWK3\'+5\U_P!QWK6W1!J/P<M7S7_<=ZT_!RU?-?\
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M&3:MPNL'RXF/[B1_4JQ5A:$G98GK&\#1N/<]GK074B(LJ(B(*<TWU9DO-OI
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M=(.1\R^*D>D6(0XUNS6[C*']KF@_>HXM(+98=M;[S>J2WQ$@S/R+A\5N\GL
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M>@IP1RCLWOR]XP;W=RZ2H:6*BHX:6F:&0PL#&-Y@!DHOHYPJ,.VPR5+0;C4
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M;\)77]4SSE*+?1$65%&-)GB/=?JL]-JDZC&DSQ'NOU6>FU(.>D1%I!=.8=^
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MI:B=P9%$PO>X\ !F5S5B.[2WN]55?-GG*_P6GXK1[T=@R2#6(B*H(B("(OT
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G1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g846460g57c33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g846460g57c33.jpg
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M*"@H*"C_P  1" $: ^0# 2(  A$! Q$!_\0 '  !  (# 0$!
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M-5 R:FECFA>,VR1N#FN'00O152B$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MEG.-?U"(M?B&XMM-BK[@\C*FA=(,^) V#M.05!+;TC)2;>D5@TBUPN.-[U4
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MK(R,=U/:Z'S^7B.A\4?";M$15BD$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M\N(X-'!HZ ,AV+7K<HJ54-'TV-0J*U'S\PB(I2P$1$ 1%^M!<X-:"23D .*
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MZNGJ!SQ2!_F*R5SK1RUKJ$1$/ B(@"(B (B( B(@"(OF66.&,OE>UC!O<XY
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MKR*:%5K2K<3<L>W:36S9#)X.WH#!JGR@]ZMX<.*S?H7^SJ^*[;\CDT1%K'T
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MRW@).])_'^"-OPGO_P >73][D^]/PGO_ ,>73][D^]:A%K<$?0^@[N/H;?\
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M35,4\1RDB>'M/,0<PKA6JMCN5LI*V YQ5$396]1&:S<Z/-2,;M2'.,C*1$5
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M7R._T28#&)*IUQNC#ZU0.R#-W+O^#\T<>[G5B((HX(6101MCB8 UK&#(- W
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M:5\)QLS;7RR'X+*=^?E 5:$4'V*OXE/[LI^)-U^TV0M8YEAMKWOX2U9#0/\
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ME9%/IM$=:&L+1XAK:W$5]'A89,1&V7:))?;.<X<<LQVGH4Z    #(#< HST
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M3Y;6PEKV]A)'F4KN <TM< 0=A!XJ/\46"SMN49;:;>"XYNRIF;>O8KL)1O\
M&N:\S3JG#)Y6QYKS.#Q1CR[X[/K'ARW2Q03$"0 ZTD@^4=S6\_G4JZ.L*QX3
MP^RD+FR5<IY2HD;N+N8= W=YXK<V6@HZ"B8RAI*>F8X9EL,88">P+/45MG+N
MXK2(,BY:[F"TE^X1$5<IA01H5]TJ\_03?S6*=UK+;:K=1UDD]'04E/.\$.DB
MA:QS@3F<R!GO4]4M0DO4M43X:YKU1LT1% 50B(@"(B (B( B(@"(B (B( B(
,@"(B (B( B(@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g846460g81e43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g846460g81e43.jpg
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M2#YFNSZW%2&U:;;=*X-NEKJ:;YT+Q*.XZI^M'B6KR/DL"^/D6VBX>'\6V/$
M M=QAEE^2<=20?NG(KN*NXN+TRK*+B]26@B(OAR$1?*KG%-23SN!<(F.>0..
M0S]2#J?5%4GY[[;_ )16?Q&I^>^V_P"45G\1JG_36^A;_0W_  EMHH/@32)2
M8NND]%34,].^*$S%TC@00'-&6S]I3A13A*#U(KV5RK?#-:81$7)P$1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 5/Z?,4&"FAP_2/R?,!+5$'<S/R6]I&?8.=6S7U<5#0U%74NU(((W2/=S-
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MV- V*#1722Q5;_[/5DO@S/N90-H_> [P.=5.OK25$M)4PU%.\LFB>'L<-[7
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M;'(Q10.H[@YHNU,W-_#EF;M<#GYQ^*L!9,X.$N&1Y^VN54G"74SEIW<X8\>
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M8T9N<XY #G)7+Q!?Z.RPYSNUYR,V0M/E._ =*I+&59?L4RN;5W".&BSS;2Q
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MS/[5_P /O_H_J(BSS'*&\(G]?VKS4_;*J96SX1/Z_M7FI^V54RVL;PD>FPO
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MKQJ!$1 $1$ 1$0!:!T&84%LLYO59'E65S<H@1M9#P^EOZLE4&C_#[L2XIHZ
M@^+ZW*3D<(V[3W[!UE:NC8V*-L<;0UC0&M:!D !N"H9MNEP(RNTK^%=TO/J?
MI1O'V*(,*6"6LDU7U+_(IXC\-_X#>?ZJ1O<UC'.>0UK1F2=P"RUI,Q2_%&))
M9HW'Q"GSBIF_-SVNZW';U9#@JN-3WLN?1%#"Q^_GSZ+J1NXUM1<:Z>LK972U
M$SR][W;R2O.BEVC3!\N++V(Y-9ENI\GU,@YN#1TGT#,K7E)0CM]$>AG.-4>)
M\DCK:+-'TF)9Q<+FU\=GC=U&=P^".CG/8.C1-)3PTE-'3TL3(8(VAK(V#(-
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M6]69@[0T]Q94XHGU6[_%('9D]#G\.H=ZN.V6^DM=''26^GCIZ=@R:R-N0_\
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MMT[N3>2'PRY9\G(-Q])!Z"41?8R<7M'49.#4H]45[:\68IP93LM>(K#47"&
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F&T9JS412WO=C9/DRXK9-A$11$ 1$0!$1 $1$ 1$0!$1 $1$!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
